Variability in the effect of muscle relaxants Factors - Anestezjologia i ...

Anestezjologia i Ratownictwo 2009; 3: 42-56 

Anestezjologia • Ratownictwo • Nauka • Praktyka / Anaesthesiology • Rescue Medicine • Science • Practice 

A R T Y K U Ł P O G L Ą D O W Y / R E V I E W PA P E R 

Wpłynęło/Submitted: 12.01.2009 • Poprawiono/Corrected: 18.01.2009 • Zaakceptowano/Accepted: 18.01.2009 

© Akademia Medycyny 

Variability in the effect of muscle relaxants 

Factors involved in the pharmacodynamic 

profile of neuromuscular blocking agents 

Leo H.D.J. Booij 1 , Leon Drobnik 2 

1 Department of Anesthesiology, Radboud University Nijmegen, The Netherlands 

2 Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Polska 

References/Piśmiennictwo 

1. Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology 1942; 3: 418-20. 

2. Griffith HR. Succinylcholine – A controllable muscle relaxant. Can Med Assoc J 1954; 71: 28-32. 

3. Beemer GH, Bjorksten AR, Crankshaw DP. Pharmacodynamics of atracurium during propofol, thiopentone and opioid anaesthesia. 

Br J Anaesth 1990; 65: 675-83. 

4. Fawcett WJ, Dash A, Francis GA, Liban JB, Cashman JN. Recovery from neuromuscular blockade: residual curarization following 

atracurium or vecuronium by bolus dosing or infusions. Acta Anaesthesiol Scand 1995; 39: 288-93. 

5. Lighthall GK, Jamieson MA, Katolik J, Brock-Utne JG. A comparison of the onset and clinical duration of high doses of cisatracurium 

and rocuronium. J Clin Anesth 1999; 11: 220-5. 

6. Schumacher PM, Stadler KS, Wirz R, Leibundgut D, Pfister CA, Zbinden AM. Model-based control of neuromuscular block using 

mivacurium: design and clinical verification. Eur J Anaesthesiol 2006; 23: 691-9. 

7. Adamus M, Belohlavek R, Koutna J, Vujcikova M, Janaskova E. Cisatracurium vs. Rocuronium: A prospective, comparative, randomized 

study in adult patients under total intravenous anaesthesia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150: 

333-8. 

8. Maybauer DM, Geldner G, Blobner M, Pühringer F, Hofmockel R, Rex C, Wulf HF, Eberhart L, Arndt C, Eikermann M. Incidence 

and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia 

2007; 62: 12-17. 

9. Henthorne TK, Krejcie TC, Avram MJ. Early drug distribution: A generally neglected aspect of pharmacokinetics of particular relevance 

to intravenously administered anesthetic agents. Clin Pharmacol Ther 2008; 84: 18-22. 

10. Katz RL, Norman J, Seed RF, Conrad L. A comparison of the effects of suxamethonium and tubocurarine in patients in London and 

New York. Br J Anaesth 1969; 41: 1041-7. 

11. Fiset P, Donati F, Balendran P, Meistelman C, Lira E, Bevan DR. Vecuronium is more potent in Montreal than in Paris. Can J Anaesth 

1991; 38: 717-21. 

12. Salib Y, Frossard J, Plaud B, Debaene B, Meistelman C, Donati F. Neuromuscular effects of vecuronium and neostigmine in Montreal 

and Paris. Can J Anaesth 1994; 41: 908-12. 

13. Hughes BW, Kusner LL, Kaminski HJ. Molecular architecture of the neuromuscular junction. Muscle Nerve 2006; 33: 445-61. 

14. Paton WD, Waud DR. The margin of safety of neuromuscular transmission. J Physiol 1967; 191: 59-90. 

15. Paul M, Kindler CH, Fokt RM, Dresser MJ, Dipps NCJ, Yost CS. The potency of new muscle relaxants on recombinant muscle-type 

acetylcholine receptors. Anesth Analg 2002; 94: 597-603. 

16. Nigrovic V, Proost JH, Amann A, Bhatt SB. Volume of the effect compartment in simulations of neuromuscular block. Theoret Biol 

Med Mod 2005; 2: 41. 

17. Waud BE, Waud DR. The margin of safety of neuromuscular transmission in the muscle of the diaphragm. Anesthesiology 1972; 37: 

17-422. 

18. Derrington MC, Hindocha N. Comparison of neuromuscular block in the diaphragm and hand after administration of tubocurarine, 

pancuronium and alcuronium. Br J Anaesth 1990; 64: 294-9. 

19. Wright PM, Caldwell JE, Miller RD. Onset and duration of rocuronium and succinylcholine at the adductor pollicis and laryngeal 

adductor muscles in anesthetized humans. Anesthesiology 1994; 81: 1110-15. 

20. Hemmerling TM, Schmidt J, Hanusa C, Wolf T, Schmitt H. Simultaneous determination of neuromuscular block at the larynx, diaphragm, 

42



adductor pollicis, orbicularis oculi and corrugator supercilii muscles. Br J Anaesth 2000; 85: 856-60. 

21. Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI. Activation and inhibition of human muscular 

and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology 2006; 104: 724-33. 

22. Pühringer FK, Heier T, Dodgson M, Erkola O, Goonetilleke P, Hofmockel R, Gaetke MR, Mortense CR, Upadhyaya B, Erikson LI. 

Double-blind comparison of the variability in spontaneous recovery of cisatracurium- and vecuronium-induced neuromuscular block 

in adult and elderly patients. Acta Anaesthesiol Scand 2002; 46: 364-77. 

23. Yodlowski EH, Mortimer JT. The relationship between receptor occlusion and the frequency sweep electromyogram during competitive 

neuromuscular blockade. Anesthesiology 1981; 34: 23-8. 

24. Silverman DG, Swift CA, Dubow HD, O’Connor TZ, Brull SJ. Variability of onset times within and amongst relaxant regimens. J Clin 

Anesth 1992; 4: 28-33. 

25. Diefenbach C, Mellinghoff H, Buzello W. Variability of pipecuronium neuromuscular blockade. Acta Anaesthesiol Scand 1993; 37: 

189-91. 

26. Arain SR, Kern S, Ficke DJ, Ebert TJ. Variability of duration of action of neuromuscular-blocking drugs in elderly patients. Acta 

Anesthesiol Scand 1995; 49: 312-15. 

27. Warran P, Theeman M, Bold AM, Jones S. Hypercholinesterasaemia and suxamethonium resistance. Anaesthesia 1987; 42: 855-7. 

28. Yao FS, Savarese JJ. Pseudocholinesterase hyperactivity with succinylcholine resistance: an unusual cause of difficult intubation. J Clin 

Anesth 1997; 9: 328-30. 

29. Naguib M , Gomaa M, Samarkandi AH, Bevan DR, Akkielah AK, Watson C, Billecke S, La Du Jr BN. Increased plasma cholinesterase 

activity and mivacurium resistance: Report of a family. Anesth Analg 1999; 89: 1579-82. 

30. Østergaard D, Ibsen M, Skovgaard L, Viby-Mogensen J. Plasma cholinesterase activity and duration of action of mivacurium in 

phenotypically normal patients. Acta Anaesthesiol Scand 2002; 46: 679-83. 

31. Østergaard D, Viby-Mogensen J, Rasmussen SN, Gätke MR, Varin F. Pharmacokinetics and pharmacodynamics of mivacurium in 

patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. 

Anesthesiology 2005; 102: 1124-32. 

32. Chung DY, Hardman J. Prolonged paralysis following mivacurium administration. Anaesth Intensive Care 2002; 30: 360-3. 

33. Sener EB, Ustun E, Kocamanoglu S, Tur A. Prolonged apnea following succinylcholine administration in undiagnosed acute 

organophosphate poisoning. Acta Anaesthesiol Scand 2002; 46: 1046-8. 

34. Jackson SH, Bailey GW, Stevens G. Reduced plasma cholinesterase following haemodilutional cardiopulmonary bypass. Anaesthesia 

1982; 37: 319-21. 

35. Rump AF, Schierholz J, Biederbick W, Theisohn M, Diefenbach C, Abel M, Börner U, Buzello W, Klaus W. Pseudocholinesterase-activity 

reduction during cardiopulmonary bypass: the role of dilutional processes and pharmacological agents. Gen Pharmacol 1999; 32: 

65-9. 

36. Diefenbach C, Abel M, Rump AF, Grond S, Korb H, Buzello W. Changes in plasma cholinesterase activity and mivacurium neuromuscular 

block in response to normothermic cardiopulmonary bypass. Anesth Analg 1995; 80: 1088-91. 

37. Shearer ES, Russell GN. The effect of cardiopulmonary bypass on cholinesterase activity. Anaesthesia 1993; 48: 293-6. 

38. Lumley J. Prolongation of suxamethonium following plasma exchange. Br J Anaesth 1980; 52: 1149-50. 

39. Evans RT, Robinson A. The combined effects of pregnancy and repeated plasma exchange on serum cholinesterase activity. Acta 

Anaesthesiol Scand 1984; 28: 44-6. 

40. Evans RT, MacDonald R, Robinson A. Suxamethonium apnoea associated with plasmaphoresis. Anaesthesia 1980; 35: 198-201. 

41. Collard CD, Baker BW 3rd, Johnson D, Bressler R, Harati Y. Cumulative reduction in serum cholinesterase following repeated therapeutic 

plasma exchange. J Clin Anesth 1996; 8: 44-8. 

42. Naik B, Hirshhorn S. Prolonged neuromuscular block due to cholinesterase depletion by plasmapheresis. J Clin Anesth 2002; 14: 

381-4. 

43. Baraka A. Suxamethonium block in the myasthenic patient. Correlation with plasma cholinesterase. Anaesthesia 1992; 47: 217-9. 

44. McCoy EP, Mirakhur RK. Comparison of the effects of neostigmine and edrophonium on the duration of action of suxamethonium. 

Acta Anaesthesiol Scand 1995; 39: 744-7. 

45. Fleming NW, Macres S, Antognini JF, Vengco J. Neuromuscular blocking action of suxamethonium after antagonism of vecuronium 

by edrophonium, pyridostigmine or neostigmine. Br J Anaesth 1996; 77: 492-5. 

46. Szenohradszky J, Fogarty D, Kirkegaard-Nielsen H, Brown R, Sharma ML, Fisher DM. Effect of edrophonium and neostigmine on the 

pharmacokinetics and neuromuscular effects of mivacurium. Anesthesiology 2000; 92: 708-14. 

47. Bang U, Viby-Mogensen J, Wirén JE. The effect of bambuterol on plasma cholinesterase activity and suxamethonium-induced 

neuromuscular blockade in subjects heterozygous for abnormal plasma cholinesterase. Acta Anaesthesiol Scand 1990; 34: 600-4. 

48. Staun P, Lennmarken C, Eriksson LI, Wirén JE. The influence of 10 mg and 20 mg of bambuterol on the duration of succinylcholineinduced 

neuromuscular blockade. Acta Anaesthesiol Scand 1990; 34: 498-500. 

49. Østergaard D, Rasmussen SN, Viby-Mogensen J, Pedersen NA, Boysen R. The influence of drug-induced low plasma cholinesterase 

activity on the pharmacokinetics and pharmacodynamics of mivacurium. Anesthesiology 2000; 92: 1581-7. 

43



50. Kambam JR, Parris WCV, Franks JJ, Sastry BVR, Naukam R, Smith BE. The inhibitory effect of metroclopramide on plasma cholinesterase 

activity. Can J Anaesthesiol 1988; 35: 476-8. 

51. Kao YJ, Turner DR. Prolongation of succinylcholine block by metoclopramide. Anesthesiology 1989; 70: 905-8. 

52. Kao YJ, Tellez J, Turner DR. Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism. Br J Anaesth 

1990; 65: 220-4. 

53. Skinner HJ, Girling KJ, Whitehurst A, Nathanson MH. Influence of metoclopramide on plasma cholinesterase and duration of action 

of mivacurium. Br J Anaesth 1999; 82: 542-5. 

54. Motamed C, Kirov K, Combes X, Dhonneur G, Duvaldestin P. Effect of metoclopramide on mivacurium-induced neuromuscular block. 

Acta Anaesthesiol Scand 2002; 46: 214-6. 

55. El Ayass N, Hendrickx P. Decreased mivacurium infusion rate and delayed neuromuscular recovery after metoclopramide: a randomized 

double blind placebo-controlled study. Eur J Anaesthesiol 2005; 22: 197-201. 

56. Donati F, Bevan DR. Controlled succinylcholine infusion in a patient receiving echothiophate eye drops. Can Anaesth Soc J 1981; 28: 

488-90. 

57. Messer GJ, Stoudemire A, Knos G, Johnson GC. Electroconvulsive therapy and the chronic use of pseudocholinesterase-inhibitor 

(echothiophate iodide) eye drops for glaucoma. A case report. Gen Hosp Psychiatry 1992; 14: 56-60. 

58. Motamed C, Kirov K, Combes X, Feiss P, Duvaldestin P. Interaction between mivacurium and pancuronium: impact of the order of 

administration. Eur J Clin Pharmacol 2005; 61: 175-7. 

59. Doenicke A, Gesing H, Krumey I, Schmidinger S. Influence of aprotinin (Trasylol) on the action of suxamethonium. Br J Anaesth 1970; 

42: 948-60. 

60. Crowe S, Collins L. Suxamethonium and donepezil: a cause of prolonged paralysis. Anesthesiology 2003; 98: 574-5. 

61. Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR. Cardiovascular and neuromuscular effects of 

esmolol during induction of anesthesia. J Clin Pharmacol 1986; 26: 351-7. 

62. Kambam JR, Franks JJ, Naukam R, Sastry BV. Effect of quinidine on plasma cholinesterase activity and succinylcholine neuromuscular 

blockade. Anesthesiology 1987; 67: 858-60. 

63. Kim KS, Kim KH, Shin WJ, Yoo HK. Neuromuscular interactions between mivacurium and esmolol in rabbits. Anaesthesia 1998; 53: 

140-5. 

64. Vigouroux D, Voltaire L. [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide]. Ann 

Fr Anesth Reanim 1995; 14: 508-10. 

65. Koseoglu V, Chiang J, Chan KW. Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide. Bone Marrow Transplant 

1999; 24: 1367-8. 

66. Evans RT, Wroe JM. Plasma cholinesterase changes during pregnancy. Their interpretation as a cause of suxamethonium-induced 

apnoea. Anaesthesia 1980; 35: 651-4. 

67. Ganga CC, Hayduk JV, Marx GF, Sklar GS. A comparison of the response to suxamethonium in post-partum and gynaecological 

patients. Anaesthesia 1982; 37: 903-6. 

68. McGehee DS, Krasowski MD, Fung DL, Wilson B, Gronert GA, Moss J. Cholinesterase inhibition by potato glycoalkaloids slows 

mivacurium metabolism. Anesthesiology 2000; 93: 510-9. 

69. Niazi A, Leonard IE, O’Kelly B. Prolonged neuromuscular blockade as a result of malnutrition-induced pseudocholinesterase deficiency. 

J Clin Anesth 2004; 16: 40-2. 

70. Blanloeil Y, Delaroche O. [Decrease in plasmatic cholinesterase activity in severe bacterial infections: comparison with the decrease 

observed in severe liver cirrhosis]. Ann Fr Anesth Reanim 1996; 15: 220-2. 

71. van Gammeren AJ, Cobbaert CM, Schrauwen CJ, Voets MA, Ermens AA. Fresh frozen plasma transfusion for reversal of prolonged 

post-anaesthesia apnoea. Transfus Med 2008; 18: 134-6. 

72. Smith DC, Ridley SA, Donaldson KF. Fresh frozen plasma and edrophonium in a patient with a plasma cholinesterase deficiency. 

Anaesthesia 1993; 48: 511-3. 

73. Naguib M, Gomaa M, Samarkandi AH, Bevan DR, Akkielah AK, Watson C, Billecke S, La Du BN Jr. Increased plasma cholinesterase 

activity and mivacurium resistance: report of a family. Anesth Analg 1999; 89: 1579-82. 

74. Pedersen SE, Cohen JB. d-Tubocurarine binding sites are located at alpha-gamma and alpha-delta subunit interfaces of the nicotinic 

acetylcholine receptor. Proc Natl Acad Sci USA 1990; 87: 2785-9. 

75. Fletcher GH, Steinbach JH. Ability of nondepolarizing neuromuscular blocking drugs to act as a partial agonist at fetal and adult mouse 

muscle nicotinic receptors. Mol Pharmacol 1996; 49: 936-47. 

76. Garland CM, Foreman RC, Chad JE, Holden-Dye L, Walker R. The actions of muscle relaxants at nicotinic acetylcholine receptor 

isoforms. Eur J Pharmacol 1998; 357: 83-92. 

77. Placzek AN, Grassi F, Papke T, Mayer EM, Papke RL. A single point mutation confers properties of the muscle-type nicotinic acetylcholine 

receptor to homomeric α7 receptors. Mol Pharmacol 2004; 66: 169-77. 

78. Dilger JP, Vidal AM, Liu M, Mettewie C, Suzuki T, Pham A, Demazumder D. Roles of amino acids and subunits in determining the 

inhibition of nicotinic acetylcholine receptors by competitive antagonists. Anesthesiology 2007; 106: 1186-95. 

44



79. Bentley JB, Borel JD, Vaughan RW, Gandolfi AJ. Weight, pseudocholinesterase activity, and succinylcholine requirement. Anesthesiology 

1962; 57: 48-9. 

80. Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg 2006; 102: 438-42. 

81. Rose JB, Theroux MC, Katz MS. The potency of succinylcholine in obese adolescents. Anesth Analg 2000; 90: 576-8. 

82. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Pedersen HS. Anthropometric variables as predictors for the 

duration of action of atracurium-induced neuromuscular block. Anesth Analg 1996; 83: 1076-80. 

83. Varin F, Ducharme J, Théoret Y, Besner JG, Bevan DR, Donati F. Influence of extreme obesity on the body disposition and neuromuscular 

blocking effect of atracurium. Clin Pharmacol Ther 1990; 48: 18-25. 

84. Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The effects of cisatracurium on morbidly obese women. Anesth Analg 

2004; 99: 1090-4. 

85. Barrio J, San Miguel G, Molina I, Asensio I, Gramuntell F, García V. [Clinical effect of mivacurium in morbidly obese patients]. Rev 

Esp Anestesiol Reanim 2006; 53: 297-300. 

86. Blobner M, Felber AR, Schneck HJ, Jelen-Esselborn S. [Dose-response relationship of atracurium in underweight, normal and overweight 

patients]. Anasthesiol Intensivmed Notfallmed Schmerzther 1994; 29: 338-42. 

87. Schwartz AE, Matteo RS, Ornstein E, Halevy JD, Diaz J. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical 

patient. Anesth Analg 1992; 74: 515-8. 

88. Weinstein JA, Matteo RS, Ornstein E, Schwartz AE, Goldstoff M, Thal G. Pharmacodynamics of vecuronium and atracurium in the 

obese surgical patient. Anesth Analg 1988; 67: 1149-53. 

89. Jain AK, Hussain S, Ahuja S. Undernutrition in children - effect on vecuronium induced neuromuscular blockade. Anaesth Intensive 

Care 1999; 27: 381-4. 

90. Pühringer FK, Keller C, Kleinsasser A, Giesinger S, Benzer A. Phaermacokinetics of rocuronium bromide in obese female patients. Eur 

J Anaesthesiol 1999; 16: 507-10. 

91. Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The pharmacodynamic effects of rocuronium when dosed according 

to real body weight or ideal body weight in morbidly obese patients. Anesth Analg 2004; 99: 1086-9. 

92. Pühringer FK, Khuenl-Brady KS, Mitterschiffthaler G. Rocuronium bromide: time-course of action in underweight, normal weight, 

overweight and obese patients. Eur J Anaesthesiol Suppl 1995; 11: 107-10. 

93. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-84. 

94. Delbono O. Neural control of aging skeletal muscle. Aging Cell 2003; 2: 21-9. 

95. Goudsouzian NG, Standaert FG. The infant and the myoneural junction. Anesth Analg 1986; 65: 1208-17. 

96. Mishina M, Takai T, Imoto K, Noda M, Takahashi T, Numa S, Methfessel C, Sakmann B. Molecular distinction between fetal and adult 

forms of muscle acetylcholine receptor. Nature 1986; 321: 406-11. 

97. Fisher DM, OKeeffe C, Stanski DR, Cronelly R, Miller RD, Gregory GA. Pharmacokinetics and pharmacodynamics of d-tubocurarine 

in infants, children and adults. Anesthesiology 1982; 57: 203-8. 

98. Vandervoort AA. Aging of the human neuromuscular system. Muscle Nerve 2002; 25: 17-25. 

99. Frolkis VV, Martynenko OA, Zamostyan VP. Aging of the neuromuscular apparatus. Gerontology 1976; 22: 244-79. 

100. Rupp SM, Castagnoli KP, Fisher DM, Miller RD. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger 

and elderly adults. Anesthesiology 1987; 67: 45-9. 

101. Bell PF, Mirakhur RK, Clarke RS. Dose-response studies of atracurium, vecuronium and pancuronium in the elderly. Anaesthesia 1989; 

44: 925-7. 

102. Kitts JB, Fisher DM, Canfell PC, Spellman MJ, Caldwell JE, Heier T, Fahey MR, Miller RD. Pharmacokinetics and pharmacodynamics 

of atracurium in the elderly. Anesthesiology 1990; 72: 272-5. 

103. Gronert BJ, Brandom BW. Neuromuscular blocking drugs in infants and children. Pediatr Clin North Am 1994; 41: 73-91. 

104. Lehmann H, Cook J, Ryan E. Pseudocholinesterase in early infancy. Proc R Soc Med 1957; 50: 147-50. 

105. Meakin G, McKiernan EP, Morris P, Baker RD. Dose-response curves for suxamethonium in neonates, infants and children. Br J 

Anaesth 1989; 62: 655-8. 

106. Telford J, Keats AS. Succinylcholine in cardiovascular surgery of infants and children. Anesthesiology 1957; 18: 841-8. 

107. Cook DR, Fischer CG. Neuromuscular blocking effects of succinylcholine in infants and children. Anesthesiology 1975; 42: 662-5. 

108. Mirakhur RK, Elliott P, Lavery TD. Plasma cholinesterase activity and the duration of suxamethonium apnoea in children. Ann R Coll 

Surg Engl 1984; 66: 43-5. 

109. Meakin G, Shaw EA, Baker RD, Morris P. Comparison of atracurium-induced neuromuscular blockade in neonates, infants and children. 

Br J Anaesth 1988; 60: 171-5. 

110. Kushimo OT, Darowski MJ, Morris P, Hollis S, Meakin G. Dose requirements of atracurium in paediatric intensive care patients. Br J 

Anaesth 1991; 67: 781-3. 

111. Taivainen T, Meakin GH, Meretoja OA, Wirtavuori K, Perkins RJ, Murphy AK, Fisher GR, Waiter MR. The safety and efficacy of 

cisatracurium 0.15 mg.kg(-1) during nitrous oxide-opioid anaesthesia in infants and children. Anaesthesia 2000; 55: 1047-51. 

45



112. Imbeault K, Withington DE, Varin F. Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in 

children during N 2O/O 2/propofol anesthesia. Anesth Analg 2006; 102: 738-43. 

113. Meretoja OA, Kalli I. Spontaneous recovery of neuromuscular function after atracurium in pediatric patients. Anesth Analg 1986; 

65:1042-1046. 

114. Odetola FO, Bhatt-Mehta V, Zahraa J, Moler FW, Custer JR. Cisatracurium infusion for neuromuscular blockade in the pediatric 

intensive care unit: A dose-finding study. Pediatr Crit Care Med 2002; 3: 250-4. 

115. Bevan JC, Reimer EJ, Smith MF, Scheepers L deV, Bridge HS, Martin GR, Bevan DR. Decreased mivacurium requirements and delayed 

neuromuscular recovery during sevoflurane anesthesia in children and adults. Anesth Analg 1998; 87: 772-8. 

116. Hofmockel VR, Pohl B, Benad G. [Mivacurium in pediatric anesthesia]. Anaesthesiol Reanim 1996; 21: 11-13. 

117. Brandom BW, Meeretoja OA, Simhi E, Taivainen T, Wolfe SR, Woelfel SK, Gronert BJ, Cook DR. Age related variability in the effects 

of mivacurium in paediatric surgical patients. Can J Anaesthesiol 1998; 45: 410-6. 

118. Alilimoff JK, Goudsouzian NC. Continuous infusion of mivacurium in children. Br J Anaesth 1989; 63: 520-4. 

119. Brandom BW, Sarner JB, Woelfel SK, Dong ML, Horn MC, Borland LM, Cook DR, Foster VJ, McNulty BF, Weakly JN. Mivacurium 

infusion requirements in pediatric surgical patients during nitrous oxide-halothane and during nitrous oxide-narcotic anesthesia. 

Anesth Analg 1990;71: 16-22. 

120. Markakis DA, Lau M, Brown R, Luks AM, Sharma ML, Fisher DM. The pharmacokinetics and steady state pharmacodynamics of 

mivacurium in children. Anesthesiology 1998; 88: 978-83. 

121. Koscielniak-Nielsen ZJ, Bevan JC, Popovic V, Baxter MR, Donati F, Bevan DR. Onset of maximum neuromuscular block following 

succinylcholine or vecuronium in four age groups. Anesthesiology 1993; 79: 229-34. 

122. Meretoja OA. Is vecuronium a long-acting neuromuscular blocking agent in neonates and infants? Br J Anaesth 1989; 62: 184-7. 

123. Fisher DM, Miller RD. Neuromuscular effects of vecuronium (ORG NC45) in infants and children during N,O, halothane anesthesia. 


124. Meretoja OA. Vecuronium infusion requirements in pediatric patients during fentanyl-N 2O-O 2 anesthesia. Anesth Analg 1989; 

68:20-24. 

125. Pittet JF, Tassonyi E, Morel DR, Gemperle G, Rouge JC. Neuromuscular effect of pipecuronium bromide in infants and children during 

nitrous oxide-alfentanil anesthesia. Anesthesiology 1990; 72: 432-5. 

126. Meretoja OA, Erkola O. Pipecuronium revisited: dose-response and maintenance requirement in infants, children, and adults. J Clin 

Anesth 1997; 9: 125-9. 

127. Tassonyi E, Pittet JF, Schopfer CN, Rouge JC, Gemperle G, Wilder-Smith OH, Morel DR. Pharmacokinetics of pipecuronium in infants, 

children and adults. Eur J Drug Metab Pharmacokinet 1995; 20: 203-8. 

128. Sarner JB, Brandom BW, Dong ML, Pickle D, Cook DR, Weinberger MJ. Clinical pharmacology of pipecuronium in infants and children 

during halothane anesthesia. Anesth Analg 1990; 71: 362-6. 

129. Meretoja OA. Neuromuscular blocking agents in paediatric patients: influence of age on the response. Anaesth Intens Care 1990; 18: 

440-8. 

130. Taivainen T, Meretoja OA, Erkola O, Rautoma P, Juvakoski M, Rocuronium in infants, children and adults during balanced anaesthesia. 

Paediatr Anaesth 1996; 6: 271-5. 

131. Driessen JJ, Robertson EN, van Egmond J, Booij LH. The time course of action and recovery of rocuronium 0.3 mg.kg -1 in infants and 

children during halothane anesthesia measured with acceleromyography. Paediatr Anaesth 2000; 10: 493-7. 

132. Rapp HJ, Altenmueller CA, Waschke C. Neuromuscular recovery following rocuronium bromide single dose in infants. Paediatr Anaesth 

2004; 14: 329-35. 

133. Booij LHDJ. Neuromuscular transmission and its pharmacological blockade. Part 4: use of relaxants in paediatric and elderly patients, 

in obstetrics, and in the intensive care unit. Pharm World Sci 1997; 19: 45-52. 

134. Cope TM, Hunter JM. Selecting neuromuscular-blocking drugs for elderly patients. Drugs Aging 2003; 20: 125-40. 

135. Viby-Mogensen J. Correlation of succinylcholine duration of action with plasma cholinesterase activity in subjects with the genotypically 

normal enzyme. Anesthesiology 1980; 53: 517-20. 

136. Matteo RS, Backus WW, McDaniel DD, Brotherton WP, Abraham R, Diaz J. Pharmacokinetics and pharmacodynamics of d-tubocurarine 

and metocurine in the elderly. Anesth Analg 1985; 64: 22-8. 

137. Slavov V, Khalil M, Merle JC, Agostini MM, Ruggier R, Duvaldestin P. Comparison of duration of neuromuscular blocking effect of 

atracurium and vecuronium in young and elderly patients. Br J Anaesth 1994; 73: 608-12. 

138. Parker CJ, Hunter JM, Snowdon SL. Effect of age, sex and anaesthetic technique on the pharmacokinetics of atracurium. Br J Anaesth 

1992; 69: 439-43. 

139. Sorooshian SS, Stafford MA, Eastwood NB, Boyd AH, Hull CJ, Wright PM. Pharmacokinetics and pharmacodynamics of cisatracurium 

in young and elderly adult patients. Anesthesiology 1996; 84: 1083-91. 

140. McLeod K, Hull CJ, Watson MJ. Effects of aging on the pharmacokinetics of pancuronium. Br J Anaesth 1979; 51: 435-8. 

141. Duvaldestin P, Saada J, Berger JL, D’Hollander A, Desmonts JM. Pharmacokinetics, pharmacodynamics and dose-response relationships 

of pancuronium in control and elderly subjects. Anesthesiology 1982; 56: 36-40. 

46



142. Ornstein E, Matteo RS, Schwartz AE, Jamdar SC, Diaz J. Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan) 

in elderly surgical patients. Anesth Analg 1992; 74: 841-4. 

143. McCarthy G, Elliott P, Mirakhur RK, Cooper R, Sharpe TD, Clarke RS. Onset and duration of action of vecuronium in the elderly: 

comparison with adults. Acta Anaesthesiol Scand 1992; 36: 383-6. 

144. Matteo RS, Ornstein E, Schwartz AE, Ostapkovich N, Stone JG. Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) 


145. Bevan DR, Fiset P, Balendran P, Law-Min JC, Ratcliffe A, Donati F. Pharmacodynamic behaviour of rocuronium in the elderly. Can J 

Anaesth 1993; 40: 127-32. 

146. Lien CA, Matteo RS, Ornstein E, Schwartz AE, Diaz J. Distribution, elimination, and action of vecuronium in the elderly. Anesth Analg 

1991; 73: 39-42. 

147. Matteo RS, Ornstein E, Schwartz AE, Ostapkovich N, Stone JG. Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) 


148. Zarday Z, Deery A, Tellis I, Soberman R, Foldes FF. Plasma and red cell cholinesterase activity in uremic patterns (effects of hemodialysis 

and renal transplantation). J Med 1975; 6: 337-49. 

149. Chang RY, Chern SC, Chiang YY, Liou MD, Tseng KF, Tsai SK. Neuromuscular interactions between succinylcholine and esmolol in 

the rat. Acta Anaesthesiol Sin 1994; 32: 203-8. 

150. Hunter JM, Jones RS, Utting JE. Use of atracurium in patients with no renal function. Br J Anaesth 1982; 54: 1251-8. 

151. Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with 

azathioprine. Br J Anaesth 1987; 59: 995-1003. 

152. Lepage JY, Malinge M, Cozian A, Pinaud M, Blanloeil Y, Souron R. Vecuronium and atracurium in patients with end-stage renal failure. 

A comparative study. Br J Anaesth 1987; 59: 1004-10. 

153. Sztark F, Cantini O, Bourdallé-Badie C, Gardien PL, Erny P. [Recovery of neuromusuclar blockade after continuous infusion of 

cisatracurium in renal failure]. Ann Fr Anesth Réanim 2001; 20: 446-51. 

154. Cook DR, Freeman JA, Lai AA, Kang Y, Stiller RL, Aggarwal S, Harrelson JC, Welch RM, Samara B. Pharmacokinetics of mivacurium 

in normal patients and in those with hepatic or renal failure. Br J Anaesth 1992; 69: 580-5. 

155. Blobner M, Jelen-Esselborn S, Mann R, Kling M, Schneider G, Schneck HJ, Kochs E. [Neuromuscular and cardiovascular effect of 

mivacurium in anesthesia induction in patients with renal failure]. Anasthesiol Intensivmed Notfallmed Schmerzther 1996; 31: 

15-21. 

156. Blobner M, Jelen-Esselborn S, Schneider G, Mann R, Kling M, Luppa P, Schneck HJ, Kochs E. Effect of renal function on neuromuscular 

block induced by continuous infusion of mivacurium. Br J Anaesth 1995; 74: 452-4. 

157. Miller RD, Stevens WC, Way WL. The effect of renal failure and hyperkalemia on the duration of pancuronium neuromuscular blockade 

in man. Anesth Analg 1973; 52: 661-6. 

158. Caldwell JE, Canfell PC, Castagnoli KP, Lynam DP, Fahey MR, Fisher DM, Miller RD. The influence of renal failure on the 

pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. 


159. Wierda JMKH, Karliczek GF, Vandenbrom RHG, Pinto I, Kersten-Kleef UW, Meijer DK, Agoston S. Pharmacokinetics and cardiovascular 

dynamics of pipecuronium bromide during coronary artery surgery. Can J Anaesth 1990; 37: 183-91. 

160. Cameron EM, Lisbon A, Moorman R, Young JD. Prolonged neuromuscular blockade with pipecuronium in a patient with renal 

insufficiency. Eur J Anaesthesiol 1994; 11: 237-9. 

161. Khuenl-Brady K, Castagnoli KP, Canfell PC, Caldwell JE, Agoston S, Miller RD. The neuromuscular blocking effects and pharmacokinetics 

of ORG 9426 and ORG 9616 in the cat. Anesthesiology 1990; 72: 669-74. 

162. Wierda JMKH, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426, 

a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J 

Anaesth 1991; 38: 430-5. 

163. Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with 

azathioprine. Br J Anaesth 1987; 59: 995-1003. 

164. Fahey MR, Morris RB, Miller RD, Nguyen TL, Upton RA. Pharmacokinetics of ORG NC45 (norcuron) in patients with and without 

renal failure. Br J Anaesth 1981; 53: 1049-52. 

165. Lynam DP, Cronnelly R, Castagnoli KP, Canfell PC, Caldwell J, Arden J, Miller RD. The pharmacodynamics and pharmacokinetics of 

vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 1988; 69: 

227-31. 

166. Slater RM, Pollard BJ, Doran BR. Prolonged neuromuscular blockade with vecuronium in renal failure. Anaesthesia 1988; 43: 250-1. 

167. Beauvoir CPeray PDaures JP, Peschaud JL, D’Athis F. Pharmacodynamics of vecuronium in patients with and without renal failure: 

a meta-analysis. Can J Anaesth 1993; 40: 696-702. 

168. Sakamoto H, Takita K, Kemmotsu O, Morimoto Y, Mayumi T. Increased sensitivity to vecuronium and prolonged duration of its action 

in patients with end-stage renal failure. J Clin Anesth 2001; 13: 193-7. 

47



169. Khuenl-Brady KS, Pomaroli A, Pühringer F, Mitterschiffthaler G, Koller J. The use of rocuronium (ORG 9426) in patients with chronic 

renal failure. Anaesthesia 1993; 48: 873-5. 

170. Robertson EN, Driessen JJ, Booij LHD. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal 

failure. Eur J Anaesthesiol 2005; 22: 4-10. 

171. Robertson EN, Driessen JJ, Vogt M, De Boer H, Scheffer GJ. Pharmacodynamics of rocuronium 0.3mgkg_1 in adult patients with and 

without renal failure. Eur J Anaesth 2005; 22: 929-32. 

172. Kocabas S, Yedicocuklu D, Askar FZ. The neuromuscular effects of 0.6mg kg (-1 ) rocuronium in elderly and young adults with or without 

renal failure. Eur J Anaesth 2008; 25: 940-6. 

173. Cooper RA, Maddineni VR, Mirakhur RK, Wierda JMKH, Brady M, Fitzpatrick KTJ. Time course of neuromuscular effects and 

pharmacokinetics of rocuronium bromide during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth 1993; 

71: 222-6. 

174. Ward S, Neill EA. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br J Anaesth 1983; 55: 1169-72. 

175. Fisher DM, Canfell PC, Fahey MR, Rosen JI, Rupp SM, Sheiner LB, Miller RD. Elimination of atracurium in humans: Contribution of 

Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology 1986; 65: 6-12. 

176. Fahey MR, Rupp SM, Fisher DM, Miller RD, Sharma M, Canfell C, Castagnoli K, Hennis PJ. The pharmacokinetics and pharmacodynamics 

of atracurium in patients with and without renal failure. Anesthesiology 1984; 61: 699-702. 

177. O’Kelly B, Jayais P, Veroli P, Lhuissier C, Ecofrey C. Dose requirements of vecuronium, pancuronium, and atracurium during orthotopic 

liver transplantation. Anesth Analg 1991; 73: 794-8. 

178. Leroy B, Baclet L, Sonnenfeld H, Scherpereel P. Atracurium et cirrhose: etude clinique de l’action curarisante. Ann Fr Anesth Réanim 

1985; 4: 489-91. 

179. Ward S, Weatherley BC. Pharmacokinetics of atracurium and its metabolites. Br J Anaesth 1986; 58(Suppl 1): 6S-10S. 

180. Gyasi HK, Naguib M. Atracurium and severe hepatic disease: a case report. Can Anaesth Soc J 1985; 32: 161-4. 

181. Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR. Importance of the organ-independent elimination of cisatracurium. 

Anesth Analg 1996; 83: 1065-71. 

182. De Wolf AM, Freeman JA, Scott VL, Tullock W, Smith DA, Kisor DF, Kerls S, Cook DR. Pharmacokinetics and pharmacodynamics of 

cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996; 76: 624-8. 

183. Ornstein E, Lien CA, Matteo RS, Ostapkovich ND, Diaz J, Wolf KB. Pharmacodynamics and pharmacokinetics of cisatracurium in 

geriatric surgical patients. Anesthesiology 1996; 84: 520-5. 

184. Devlin JC, Head-Rapson AG, Parker CJ, Hunter JM. Pharmacodynamics of mivacurium in patients with hepatic cirrhosis. Br J Anaesth 

1993; 71: 227-31. 

185. Green DW, Fisher M, Sockalingham I. Mivacurium compared with succinylcholine in children with liver disease. Br J Anaesth 1998; 

81: 463-5. 

186. Gao L, Ramzam I, Baker B. Rocuronium plasma concentrations during three phases of liver transplantation: relationship with early 

postoperative graft liver function. Br J Anaesth 2002; 88: 764-70. 

187. Gao L, Ramzam I, Baker B. Rocuronium infusion requirements and plasma concentrations at constant levels of neuromuscular paralysis 

during three phases of liver transplantation. J Clin Anesth 2003; 15: 256-66. 

188. Duvaldestin P, Agoston S, Henzel D, Kersten UW, Desmonts JM. Pancuronium pharmacokinetics in patients with cirrhosis. Br J 

Anaesth 1978; 50: 1131-6. 

189. Somogyi AA, Shanks CA, Triggs EJ. Disposition kinetics of pancuronium bromide in patients with tota bliary obstruction. Br J Anaesth 

1977; 49: 1103-8. 

190. Westra P, Vermeer GA, de Lange AR, Scaf AH, Meijer DK, Wesseling H. Hepatic and renal disposition of pancuronium and gallamine 

in patients with extrahepatic cholestasis. Br J Anaesth 1981; 53:331-338. 

191. D’Honneur G, Khalil M, Dominique C, Haberer JP, Kleef UW, Duvaldestin P. Pharmacokinetics and pharmacodynamics of pipecuronium 

in patients with cirrhosis. Anesth Analg 1993; 77: 1203-6. 

192. Olinga P, Merema M, Hof IH, Sloof MJ, Meyer DKF, Groothuis GMM. Characterization of the uptake of rocuronium and digoxin in 

human hepatocytes: carrier specificity and comparison with in vivo data. J Pharmacol Exp Ther 1998; 285: 506-10. 

193. Lebrault C, Duvaldestin P, Henzel D, Chauvin M, Guesnon P. Pharmacokinetics and pharmacodynamics of vecuronium in patients 

with cholestasis. Br J Anaesth 1986; 58: 983-7. 

194. Hunter JM, Parker CJ, Bell CF, Jones RS, Utting JE. The use of different doses of vecuronium in patients with liver dysfunction. Br J 

Anaesth 1985; 57: 758-64. 

195. Khalil M, D’Honneur G, Duvaldestin P, Slavov V, De Hys C, Gomeni R. Pharmacokinetics and pharmacodynamics of rocuronium in 

patients with cirrhosis. Anesthesiology 1994; 80: 1241-7. 

196. van Miert MM, Eastwood NB, Boyd AH, Parker CJ, Hunter JM. The pharmacokinetics and pharmacodynamics of rocuronium in 

patients with hepatic cirrhosis. Br J Clin Pharmacol 1997; 44: 139-44. 

197. Magorian T, Wood P, Caldwell J, Fisher D, Segredo V, Szenohradszky J, Sharma M, Gruenke L, Miller R. The pharmacokinetics and 

neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 1995; 80: 754-9. 

48



198. Yang JJ, Wang YG, Zhang Z, Zhang ZJ, Liu J, Xu JG. Pharmacokinetics of rocuronium in cholestatic patients with or without hepatocellular 

injury: normal onset time of initial doses and prolonged duration time after repeated doses. J Pharm Pharmaceut Sci 2008; 11: 15-21. 

199. Pleym H, Spigset O, Kharasch ED, Dale O. Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol 

Scand 2003; 47: 241-59. 

200. Mencke T, Soltesz S, Grundmann U, Bauer M, Schlaich N, Larsen R, Fuchs-Buder T. Time course of neuromuscular blockade after 

rocuronium. A comparison between women and men. Anaesthesist 2000; 49: 609-12. 

201. Mencke T, Beerhalter U, Fuchs-Buder T. Spontaneous movements, local reactions and pain on injection of rocuronium. A comparison 

between female and male patients. Acta Anaesthesiol Scand 2001; 45: 1002-5. 

202. Mencke T, Schreiber JU, Knoll HH, Stracke C, Kleinschmidt S, Rensing H, Silomon M. Women report more pain on injection of 

a precurarization dose of rocuronium: a randomized, prospective, placebo-controlled trial. Acta Anaesthesiol Scand 2004; 48: 

1245-8. 

203. Vanlinthout LE, van Egmond J, de Boo T, Lerou JG, Wevers RA, Booij LH. Factors affecting magnitude and time course of neuromuscular 

block produced by suxamethonium. Br J Anaesth 1992; 69: 29-35. 

204. Parker CJ, Hunter JM, Snowdon SL. Effect of age, sex and anaesthetic technique on the pharmacokinetics of atracurium. Br J Anaesth 

1992; 69: 439-43. 

205. Xue FS, Zhang YM, Liao X, Liu JH, An G. Influences of age and gender on dose response and time course of effect of atracurium in 

anesthetized adult patients. J Clin Anesth 1999; 11: 397-405. 

206. Schmith VD, Fiedler-Kelly J, Phillips L, Grasela TH Jr. Prospective use of population.pharmacokinetics/pharmacodynamics in the 

development of cisatracurium. Pharm Res 1997; 14: 91-7. 

207. Adamus M, Gabrhelik T, Marek O. Influence of gender on the course of neuromuscular block following a single bolus dose of cisatracurium 

or rocuronium. Eur J Anaesthesiol 2008; 25: 589-95. 

208. Semple P, Hope DA, Clyburn P, Rodbert A. Relative potency of vecuronium in male and female patients in Britain and Australia. Br J 

Anaesth 1994; 72: 190-4. 

209. Xue FS, Liao X, Liu JH, Tong SY, Zhang YM, Zhang RJ, et al. Dose-response curve and time course of effect of vecuronium in male and 

female patients. Br J Anaesth 1998; 80: 720-4. 

210. Houghton IT, Aun CS, Oh TE. Vecuronium: an anthropometric comparison. Anaesthesia 1992; 47: 741-6. 

211. Xue FS, An G, Liao X, Zou Q, Luo LK. The pharmacokinetics of vecuronium in male and female.patients. Anesth Analg 1998; 86: 

1322-7. 

212. Xue FS, Tong SY, Liao X, Liu JH, An G, Luo LK. Dose response and time course of effect of rocuronium in male and female anesthetized 

patients. Anesth Analg 1997; 85: 667-71. 

213. Dailey PA, Fisher DM, Shnider SM, Baysinger CL, Shinohara Y, Miller RD, Abboud TK, Kim KC. Pharmacokinetics, placental transfer, 

and neonatal effects of vecuronium and pancuronium administered during cesarean section. Anesthesiology 1984; 60: 569-74. 

214. James MFM. Magnesium in obstetric anesthesia. Int J Obstet Anesth 1998; 7: 115-23 

215. Evans RT, Wroe JM. Plasma cholinesterase changes during pregnancy. Their interpretation as a cause of suxamethonium-induced 

apnoea. Anaesthesia 1980; 35: 651-4. 

216. Ganga CC, Hayduk JV, Marx GF, Sklar GS. A comparison of the response to suxamethonium in post-partum and gynaecological 

patients. Anaesthesia 1982; 37: 903-6. 

217. Leighton BL, Cheek TG, Gross JB, Apfelbaum JL, Shantz BB, Gutsche BB, Rosenberg H. Succinylcholine pharmacodynamics in 

peripartum patients. Anesthesiology 1986; 64: 202-5. 

218. Aagesen G, Ronquist G. Prolonged succinylcholine-induced paralysis in connection with caesarean section. A case report. Acta 


219. Davies P, Landy M. Suxamethonium and mivacurium sensitivity from pregnancy-induced plasma cholinesterase deficiency. Anaesthesia 

1998; 53: 1109-11. 

220. Khuenl-Brady KS, Koller J, Mair P, Pühringer F, Mitterschiffthaler G. Comparison of vecuronium- and atracurium-induced 

neuromuscular blockade in postpartum and nonpregnant patients. Anesth Analg 1991; 72: 110-3. 

221. Pan PH, Moore C. Comparison of cisatracurium-induced neuromuscular blockade between immediate postpartum and nonpregnant 

patients. J Clin Anesth 2001; 13: 112-7. 

222. Kim JH, Min KT, Ahn EK, Kim KH, Shin YS. The infusion rate of mivacurium or atracurium for cesarean section compared with 

gynecological procedures. Yonsei Med J 1999; 40: 371-2. 

223. Gin T, Derrick JL, Chan MT, Chui PT, Mak TW. Postpartum patients have slightly prolonged neuromuscular block after mivacurium. 

Anesth Analg 1998; 86: 82-5. 

224. Camp CE, Tessem J, Adenwala J, Joyce IIIrd TH. Vecuronium and prolonged neuromuscular blockade in postpartum patients. 


225. Baraka A, Tabboush Z, Sibai A, Bijjani A, Karam K. Onset of vecuronium neuromuscular block is more rapid in patients undergoing 

Caesarean section. Can J Anaesth 1992; 39: 135-8. 

226. Duvaldestin P, Demetriou M, Henzel D, Desmonts JM. The placental transfer of pancuronium and its pharmacokinetics during caesarian 

49



section. Acta Anaesthesiol Scand 1978; 22: 327-33. 

227. Hawkins JL, Adenwala J, Camp C, Joyce TH III. The effect of Ha-receptor antagonist premeditation on the duration of vecuroniuminduced 

neuromuscular blockade in postpartum patients. Anesthesiology 1989; 71: 175-7. 

228. Baraka A, Jabbour S, Tabboush Z, Sibai A, Bijjani A, Karam K. Onset of vecuronium neuromuscular block is more rapid in patients 

undergoing caesarean section. Can J Anaesth 1992; 39: 135-8. 

229. Puhringer FK, Sparr HJ, Mitterschiffthaler G, Agoston S, Benzer A. Extended duration of action of rocuronium in postpartum patients. 

Anesth Analg 1997; 84: 352-4. 

230. Gin T, Chan MT, Chan KL, Yuen PM. Prolonged neuromuscular block after rocuronium in postpartum patients. Anesth Analg 2002; 

94: 686-9. 

231. Miller RD, Agoston S, van der Pol F, Booij LH, Crul JF. Effect of different anesthetics on the pharmacokinetics and pharmacodynamics 

of pancuronium in the cat. Acta Anaesthesiol Scand 1979; 23: 285-90. 

232. Dilger JP, Vidal AM, Mody HI, Liu Y. Evidence for direct actions of general anesthetics on an ion channel protein: a new look at a unified 

mechanism of action. Anesthesiology 1994; 81: 431-42. 

233. Paul M, Fokt RM, Kindler CH, Dipp NCJ, Yost CS. Characterization of the interactions between volatile anesthetics and neuromuscular 

blockers at the muscle nicotinic acetylcholine receptor. Anesth Analg 2002; 95: 362-7. 

234. Jalkanen L, Meretoja OA. The influence of the duration of isoflurane anaesthesia on neuromuscular effects of mivacurium. Acta 


235. Plaud B, Debaene B, Donati F. Duration of anesthesia before muscle relaxant injection influences level of paralysis. Anesthesiology 

2002; 97: 616-21. 

236. Cannon JE, Fahey MR, Castagnoli KP, et al. Continuous infusion of vecuronium: the effect of anesthetic agents. Anesthesiology 1987; 

67: 503-6. 

237. Wulf H, Ledowski T, Linstedt U, Proppe D, Sitzlack D. Neuromuscular blocking effect of rocuronium during desflurane, isoflurane and 

sevoflurane anaesthesia. Can J Anaesth 1988; 45: 526-32. 

238. Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S. Interaction between nondepolarizing neuromuscular blocking 

agents and inhalational anesthetics. Anesth Analg 1989; 69: 752-5. 

239. Wierda JMKH, Richardson FJ, Agoston S. Dose response relation and time course of action of pipecuronium bromide in humans 

anaesthetized with nitrous oxide and isoflurane, halothane, or droperidol and fentanyl. Anesth Analg 1989; 68: 208-13. 

240. Pittet JF, Tassonyi E, Morel DR, Gemperle G, Richter M, Rouge JC. Pipecuronium-induced neuromuscular blockade during nitrous 

oxide-fentanyl, isoflurane, and halothane anesthesia in adults and children. Anesthesiology 1989; 71: 210-13. 

241. Shanks CA, Frager RJ, Ling DL. Continuous intravenous infusion of rocuronium (Org 9426) in patients receiving balanced, enflurane, 

or isoflurane anesthesia. Anesthesiology 1994; 78: 649-51. 

242. Van den Broek L, Wierda JMKH, Smeulers NJ, NJ, van Santen GJ, Leclercq MG, Hennis PJ. Clinical pharmacology of rocuronium (Org 

9426); study of the time course of action, dose requirement, reversibility and pharmacokinetics. J Clin Anesth 1994; 6: 288-96. 

243. Meretoja OA, Wirtavuori K, Taivainen T, Olkkola KT. Time course of potentiation of mivacurium by halothane and isoflurane in 

children. Br J Anaesth 1996; 76: 235-8. 

244. Kumar N, Mirakhur RK, Symington MJ, Loan PB, Connolly FM. A comparison of the effects of isoflurane and desflurane on the 

neuromuscular effects of mivacurium. Anaesthesia 1996; 51: 547-50. 

245. Kurahashi K, Maruta H. The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous 

infusion. Anesth Analg 1996; 82: 942-7. 

246. Kumar N, Mirakhur RK, Symington MJ, McCarthy GJ. Potency and time course of action of rocuronium during desflurane and 

isoflurane anaesthesia. Br J Anaesth 1996; 77: 488-91. 

247. Neidhart G, Pabelick C, Kuhn I, Leuwer M, Vettermann J. Effects of halothane, enflurane and isoflurane on pharmacodynamics of 

mivacurium in children. Anasthesiol Intensivmed Notfallmed Schmerzther 1996; 31: 293-7. 

248. Kansanaho M, Olkkola KT. The effect of halothane on mivacurium infusion requirements in adult surgical patients. Acta Anaesthesiol 

Scand 1997; 41: 754-9. 

249. Xue FS, Liao X, Tong SY, Liu JH, An G, Luo LK. Dose-response and time-course of the effect of rocuronium bromide during sevoflurane 

anaesthesia. Anaesthesia 1998; 53: 25-30. 

250. Wulf H, Hauschild S, Proppe D, Ledowski T. Augmentation of neuromuscular blocking effect of mivacurium by desflurane, sevoflurane, 

isoflurane in comparison with TIVA. Anesth Rean 1998; 23: 88-92. 

251. Suzuki T, Munakata K, Watanabe N, Katsumata N, Saeki S, Ogawa S. Augmentation of vecuronium-induced neuromuscular block 

during sevoflurane anaesthesia: comparison with balanced anaesthesia using propofol or midazolam. Br J Anaesth 1999; 83: 485-7. 

252. Lowry DW, Mirakhur RK, Carroll MT, McCarthy GJ, Hughes DA, O’Hare RA. Potency and time course of mivacurium block during 

sevoflurane, isoflurane and intravenous anesthesia. Can J Anaesth 1999; 46: 29-33. 

253. Bock M, Klippel K, Nitsche B, Bach A, Martin E, Motsch J. Rocuronium potency and recovery characteristics during steady-state 

desflurane, sevoflurane, isoflurane or propofol anaesthesia. Br J Anaesth 2000; 84: 43-47. 

254. Gan TJ, Madan R, Alexander R, Jhaveri R, El-Moalem H, Weatherwax K, Glass PS. Duration of action of vecuronium after an intubating 

50



dose of rapacuronium, vecuronium, or succinylcholine. Anesth Analg 2001; 92: 1199-202. 

255. Hemmerling TM, Schuettler J, Schwilden H. Desflurane reduces the effective therapeutic infusion rate (ETI) of cisatracurium more 

than isoflurane, sevoflurane, or propofol. Can J Anaesth 2001; 48: 532-7. 

256. Dragne A, Varin F, Plaud B, Donati F. Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane 

anesthesia. Can J Anaesth 2002; 49: 353-60. 

257. Motamed C, Donati F. Sevoflurane and isoflurane, but not propofol, decrease mivacurium requirements over time. Can J Anaesth 2002; 

49: 907-12. 

258. Gungor I, Bozkirli F, Celebi H, Günaydin B. Comparison of the effects of neurolept anesthesia and enflurane or sevoflurane anesthesia 

on neuromuscular blockade by rocuronium. J Anesth 2003; 17: 129-32. 

259. Hadimioglu N, Ertugrul F, Ertug Z, Yegin A, Karaguzel G, Erman M. The comparative effect of single dose mivacurium during 

sevoflurane or propofol anesthesia in children. Paediatr Anaesth 2005; 15: 852-7. 

260. Woloszczuk-Gebicka B. Mivacurium infusion requirement and spontaneous recovery of neuromuscular transmission in children 

anaesthetized with nitrous oxide and fentanyl, halothane, isoflurane or sevoflurane. Paediatr Anaesth 2002; 12: 511-8. 

261. Barrio J, SanMiguel G, Asensio I, Molina I, López F, García V. Time course and train-of-four fade of mivacurium block during sevoflurane 

and intravenous anaesthesia. Eur J Anaesthesiol 2005; 22: 303-6. 

262. Woloszczuk-Gebicka B, Wyska E, Grabowski T. Sevoflurane increases fade of neuromuscular response to TOF stimulation following 

rocuronium administration in children. A PK/PD analysis. Paediatr Anaesth 2007; 17: 637-46. 

263. Nakata Y, Goto T, Morita S. Vecuronium-induced neuromuscular block during xenon or sevoflurane anaesthesia in humans. Br J 

Anaesth 1998; 80: 238-40. 

264. Kunitz O, Baumert JH, Hecker K, Beeker T, Coburn M, Zühlsdorff A, Rossaint R. Xenon does not prolong neuromuscular block of 

rocuronium. Anesth Analg 2004; 99: 1398-401. 

265. Chaudhry IA, Nitahara K, Nagashima H, Vizi ES. Neurochemical evidence that [Ca 2+]o antagonizes the effect of neomycin on 

acetylcholine release from mouse hemidiaphragm preparation: an attempt to assess the margin to safety. Acta Anaesthesiol Scand 1995; 

39: 494-7. 

266. Amici M, Eusebi F, Miledi R. Effects of the antibiotic gentamicin on nicotinic acetylcholine receptors. Neuropharmacol 2005; 49: 

627-37. 

267. Pridgen JE. Respiratory arrest thought to be due to intraperitonea.l neomycin. Surgery 1956; 40: 571-4. 

268. Molitor H, Graessle OE, Kuna S, Mushett CW, Silber RH. Some toxicological and pharmacological properties of streptomycin. J 

Pharmacol Exp Ther 1946; 86: 151-73. 

269. Pittinger CB, Eryasa Y, Adamson R. Antibiotic-induced paralysis. Anesth Analg 1970; 49: 487-501. 

270. Lippmann M, Yang E, Au E, Lee C. Neuromuscular blocking effects of tobramycin, gentamicin, and cefazolin. Anesth Analg 1982; 61: 

767-70. 

271. Torda T. The nature of gentamicin-induced neuromuscular block. Br J Anaesth 1980; 52: 325-9. 

272. Redman RS, Silinsky EM. Decrease in calcium currents induced by aminoglycoside antibiotics in frog motor nerve endings. Br J 

Pharmacol 1994; 113: 375-8. 

273. Coleman JW, Artusio JF, Tao FT, McGovern JH, Jalandoni SR. Neomycin-induced neuromuscular blockade. Urology 1981; 17: 265-7. 

274. Wong J, Brown G. Does once-daily dosing of aminoglycosides affect neuromuscular function? J Clin Pharm Ther 1996; 21: 407-11. 

275. Singh YN, Marshall IG, Harvey AL. Some effects of the aminoglycoside antibiotic amikacin on neuromuscular and autonomic 

transmission. Br J Anaesth 1978; 50: 109-17. 

276. Lippmann M, Yang E, Au E, Lee C. Neuromuscular blocking effects of tobramycin, gentamicin, and cefazolin. Anesth Analg 1982; 61: 

767-70. 

277. Kronenfeld MA, Thomas SJ, Turndorf H. Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving 

polymyxin/amikacin sternal irrigation. Anesthesiology 1986; 65: 93-4. 

278. Dupuis JY, Martin R, Tétrault JP. Atracurium and vecuronium interaction with gentamicin and tobramycin. Can J Anaesth 1989; 36: 

407-11. 

279. Matsukawa S, Suh JH, Hashimoto Y, Kato M, Satoh D, Saito S, et al. Neuromuscular blocking actions of the aminoglycoside antibiotics 

sisomicin and micronomicin in the rabbit. Tohoku J Exp Med 1997; 181: 471-3. 

280. Dotan ZA, Hana R, Simon D, Geva D, Pfeffermann RA, Ezri T. The effect of vecuronium is enhanced by a large rather than a modest 

dose of gentamicin as compared with no preoperative gentamicin. Anesth Analg 2003; 96: 750-4. 

281. Gilbert TB, Jacobs SC, Quaddoura AA. Deafness and prolonged neuromuscular blockade following single-dose peritoneal neomycin 

irrigation. Can J Anaesth 1998; 45: 568-70. 

282. Kim KS, Shim JC, Jun JH, Lee KH, Chung CW. Rabbits treated with chronic isepamicin are resistant to mivacurium and rocuronium. 

Anesth Analg 1999; 88: 654-8. 

283. Martinez EA, Mealey KL, Wooldridge AA, Mercer DE, Cooper J, Slater MR, et al. Pharmacokinetics, effects on renal function, and 

potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized 

dogs. Am J Vet Res 1996; 57: 1623-6. 

51



284. Endo K.[Neuromuscular blocking properties of arbekacin, astromicin, isepamicin and netilmicin in the rabbit]. Jpn J Antibiot 1999; 

52: 554-561. 

285. Liu M, Kato M, Hashimoto Y. Neuromuscular blocking effects of the aminoglycoside antibiotics arbekacin, astromicin, isepamicin and 

netilmicin on the diaphragm and limb muscles in the rabbit. Pharmacology 2001; 63: 142-6. 

286. Miller RD. Antagonism of neuromuscular blockade. Anesthesiology 1976; 44: 318-29. 

287. Burkett L, Bikhazi GB, Thomas KC Jr, Rosenthal DA, Wirta MG, Foldes FF. Mutual potentiation of the neuromuscular effects of 

antibiotics and relaxants. Anesth Analg 1979; 58: 107-15. 

288. Wright JM, Collier B. The site of the neuromuscular block produced by polymyxin B and rolitetracycline. Can J Physiol Pharmacol 

1976; 54: 926-36. 

289. Lee C, Chen D, Nagel EL. Neuromuscular block by antibiotics: polymyxin B. Anesth Analg 1977; 56: 373-7. 

290. Chinyanga HM, Stoyka WW. The effect of colymycin M, gentamycin and kanamycin on depression of neuromuscular transmission 

induced by pancuronium bromide. Can Anaesth Soc J 1974; 21: 569-79. 

291. Van Nyhuis LS, Miller RD, Fogdall RP. The interaction between d-tubocurarine, pancuronium, polymyxin B, and neostigmine on 

neuromuscular function. Anesth Analg 1976; 55: 224-8. 

292. Lee C, de Silva AJ. Interaction of neuromuscular blocking effects of neomycin and polymyxin B. Anesthesiology 1979; 50: 218-20. 

293. Fogdall RP, Miller RD. Prolongation of a pancuronium-induced neuronmuscular blockade by polymyxin B. Anesthesiology 1974; 40: 

84-7. 

294. Kronenfeld MA, Thomas SJ, Turndorf H. Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving 

polymyxin/amikacin sternal irrigation. Anesthesiology 1986; 65: 93-4. 

295. Jedeikin R, Dolgunski E, Kaplan R, Hoffman S. Prolongation of neuromuscular blocking effect of vecuronium by antibiotics. Anaesthesia 

1987; 42: 858-60. 

296. Fiekers JF. Neuromuscular block produced by polymyxin B: interaction with end-plate channels. Eur J Pharmacol 1981; 70: 77-81. 

297. Durant NN, Lambert JJ. The action of polymyxin B at the frog neuromuscular junction. Br J Pharmacol 1981; 72: 41-7. 

298. Huang KC, Heise A, Shrader AK, Tsueda K. Vancomycin enhances the neuromuscular blockade of vecuronium. Anesth Analg 1990; 

71: 194-6. 

299. Albrecht RF 2nd, Lanier WL. Potentiation of succinylcholine-induced phase II block by vancomycin. Anesth Analg 1993; 77: 

1300-02. 

300. Rubbo JT, Gergis SD, Sokoll MD. Comparative neuromuscular effects of lincomycin and clindamycin. Anesth Analg 1977; 56: 

329-32. 

301. Singh YN, Marshall IG, Harvey AL. Pre- and postjunctional blocking effects of aminoglycoside, polymyxin, tetracycline and lincosamide 

antibiotics. Br J Anaesth 1982; 54: 1295-306. 

302. Fiekers JF, Henderson F, Marshall IG, Parsons RL. Comparative effects of clindamycin and lincomycin on end-plate currents and quantal 

content at the neuromuscular junction. J Pharmacol Exp Ther 1983; 227: 308-15. 

303. Prior C, Fiekers JF, Henderson F, Dempster J, Marshall IG, Parsons RL. End-plate ion channel block produced by lincosamide antibiotics 

and their chemical analogs. J Pharmacol Exp Ther 1990; 255: 1170-6. 

304. Fiekers JF. Sites and mechanisms of antibiotic-induced neuromuscular block: a pharmacological analysis using quantal content, voltage 

clamped end-plate currents and single channel analysis. Acta Physiol Pharmacol Ther Latinoam 1999; 49: 242-50. 

305. Fogdall RP, Miller RD. Prolongation of a pancuronium-induced neuromuscular blockade by clindamycin. Anesthesiology 1974 ; 41: 

407-8. 

306. al Ahdal O, Bevan DR. Clindamycin-induced neuromuscular blockade. Can J Anaesth 1995; 42: 614-7. 

307. Best JA, Marashi AH, Pollan LD. Neuromuscular blockade after clindamycin administration: a case report. J Oral Maxillofac Surg 

1999; 57: 600-3. 

308. Sloan PA, Rasul M. Prolongation of rapacuronium neuromuscular blockade by clindamycin and magnesium. Anesth Analg 2002; 94: 

123-4. 

309. Wright JM, Collier B. Characterization of the neuromuscular block produced by clindamycin and lincomycin. Can J Physiol Pharmacol 

1976; 54: 937-44. 

310. Tryba M. [Potentiation of the effect of non-depolarizing muscle relaxants by acylaminopenicillins. Studies on the example of vecuronium]. 

Anaesthesist 1985; 34: 651-5. 

311. Mackie K, Pavlin EG. Recurrent paralysis following piperacillin administration. Anesthesiology 1990; 72: 561-3. 

312. Singh YN, Harvey AL, Marshall IG. Antibiotic-induced paralysis of the mouse phrenic nerve-hemidiaphragm preparation, and 

reversibility by calcium and by neostigmine. Anesthesiology 1978; 48: 418-24. 

313. McIndewar IC, Marshall RJ. Interactions between the neuromuscular blocking drug Org NC 45 and some anaesthetic, analgesic and 

antimicrobial agents. Br J Anaesth 1981; 53: 785-92. 

314. d’Hollander A, Agoston S, Capouet V, Barvais L, Bomblet JP, Esselen M. Failure of metronidazole to alter a vecuronium neuromuscular 

blockade in humans. Anesthesiology 1985; 63: 99-102. 

315. Tang AH, Schroeder LA. The effect of lincomycin on neuromuscular transmission. Toxicol Appl Pharmacol 1968; 12: 44-7. 

52



316. Lee SI, Lee JH, Lee SC, Lee JM, Lee JH. Calcium and neostigmine antagonize gentamicin, but augment clindamycin-induced tetanic 

fade in rat phrenic nerve-hemidiaphragm preparations. J Anesth 2008; 22: 385-90. 

317. Lee C, de Silva AJ, Katz RL. Antagonism of polymyxin B-induced neuromuscular and cardiovascular depression by 4-aminopyridine 

in the anesthetized cat. Anesthesiology 1978; 49: 256-359. 

318. de Silva AJ, Lee C. Neuromuscular and cardiovascular depression produced by prolonged exposure to Polymyxin B. Can Anaesth Soc 

J 1978; 25: 303-6. 

319. Brazil OV, Fontana MD, Pavani NJ. Effect of 4-aminopyridine on the postsynaptic action of polymyxin B. Eur J Pharmacol 1989; 159: 

47-51. 

320. Booij LH, Miller RD, Crul JF. Neostigmine and 4-aminopyridine antagonism of lincomycin-pancuronium neuromuscular blockade 

in man. Anesth Analg 1978; 57: 316-21. 

321. Liu M, Dilger JP. Site selectivity of competitive antagonists for the mouse adult muscle nicotinic acetylcholine receptor. Mol Pharmacol 

2009; 75: 166-73. 

322. Liu M, Dilger JP. Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg 2008; 

107: 525-33. 

323. Waud BE, Waud DR. Interaction among agents that block end-plate depolarization competitively. Anesthesiology 1985; 63: 4-15. 

324. Stout RG, Brull SJ, and Silverman DG. Early neuromuscular recovery characteristics following administration of mivacurium and 

vecuronium. Can J Anaesth 1996; 43: 358-461. 

325. Naguib M. Neuromuscular effects of rocuronium bromide and mivacurium chloride administered alone and in combination. 


326. Stevens JB, Shephered JM, Vories PA, Walker SC, Vescovo MV. A mixture of mivacurium and rocuronium is comparable in clinical 

onset to succinylcholine. J Clin Anesth 1996; 8: 486-90. 

327. Motamed C, Donati F. Intubating conditions and blockade after mivacurium, rocuronium and their combination in young and elderly 

adults. Can J Anaesth 2000; 47: 225-31. 

328. Fletcher JE, Heard CM. The clinical effect of mixing different proportions of rocuronium and mivacurium. Paediatr Anaesth 2004; 14: 

152-7. 

329. Gibbs NM, Rung GW, Braunegg PW, Martin DE. The onset and duration of neuromuscular blockade using combinations of atracurium 

and vecuronium. Anaesth Intensive Care 1991; 19: 96-100. 

330. Breslin DS, Jiao K, Habib AS, Schultz J, Gan TJ. Pharmacodynamic interactions between cisatracurium and rocuronium. Anesth Analg 

2004; 98: 107-10. 

331. Paul M, Kindler CH, Fokt RM, Dipp NCJ, Yost CS. Isobolographic analysis of non-depolarising muscle relaxant interactions at their 

receptor site. Eur J Pharmacol 2002; 438: 35-43. 

332. Lebowitz PW, Ramsey FM, Savarese JJ, Ali HH. Potentiation of neuromuscular blockade in man produced by combinations of 

pancuronium and metocurine or pancuronium and d-tubocurarine. Anesth Analg 1980; 59: 604-9. 

333. Mirakhur RK, Pandit SK, Ferres CJ, Gibson FM. Time course of muscle relaxation with a combination of pancuronium and tubocurarine. 

Anesth Analg 1984; 63: 437-40. 

334. Mirakhur RK, Gibson FM, Ferres CJ. Vecuronium and d-tubocurarine combination: potentiation of effect Anesth Analg 1985; 64: 

711-4. 

335. Van Der Spek AF, Zupan JT, Pollard BJ, Schork MA. Interactions of vecuronium and atracurium in an in vitro nerve-muscle preparation. 

Anesth Analg 1988; 67: 240-6. 

336. Naguib M, Samarkandi AH, Bakhamees HS, Magboul MA, el-Bakry AK. Comparative potency of steroidal neuromuscular blocking 

drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids. Brit J Anaesth 1995; 75: 37-42. 

337. Kim KS, Chun YS, Chon SU, Suh JK. Neuromuscular interaction between cisatracurium and mivacurium, atracurium, vecuronium or 

rocuronium administered in combination. Anaesthesia 1998; 53: 872-8. 

338. Ono K, Manabe N, Ohta Y, Morita K, Kosaka F. Influence of suxamethonium on the action of subsequently administered vecuronium 

or pancuronium. Br J Anaesth 1989; 62: 324-6. 

339. Oris B, Crul JF, Vandermeersch E, Van Aken H, Van Egmond J, Sabbe MB. Muscle paralysis by rocuronium during halothane, enflurane, 

isoflurane, and total intravenous anaesthesia. Anesth Analg 1993; 77: 570 -3. 

340. Dubois MY, Lea DE, Kataria B, Gadde PL, Tran DQ, Shearrow T. Pharmacodynamics of rocuronium with and without prior administration 

of succinylcholine. J Clin Anesth 1995; 7: 44-8. 

341. Valinthout LE, Booij LH, van Egmond J, Robertson EN. Effect of isoflurane and sevoflurane on the magnitude and time course of 

neuromuscular block produced by vecuronium, pancuronium and atracurium. Br J Anaesth 1996; 76: 389-95. 

342. Robertson EN, Driessen JJ, Booij LH. Suxamethonium administration prolongs the duration of action of subsequent rocuronium. Eur 

J Anaesthesiol 2004; 21: 734-7. 

343. Roed J, Larsen PB, Olsen JS, Engbaek J. The effect of succinylcholine on atracurium-induced neuromuscular block. Acta Anaesthesiol 

Scand 1997; 41: 1331-4. 

344. Kanyamibwa D, Tsaousi G, Karakoulas K, Thomareis O, Parlapani A, Makedou AH, Giala M. Effects of succinylcholine on the recovery 

53



of block produced by mivacurium in rats. Methods Find Exp Clin Pharmacol 2008; 30: 187-91. 

345. Ivankovich AD, Sidell N, Cairoli VJ, Dietz AA, Albrecht RF. Dual action of pancuronium on succinylcholine block. Can Anaesth Soc 

J 1977; 24: 228-342. 

346. Erkola O, Rautoma P, Meretoja OA. Mivacurium when preceded by pancuronium becomes a long lasting muscle relaxant. Anesthesiology 

1996; 84: 562-5. 

347. Wangler MD, Thapar P, Skerman JH. Decreased mivacurium constant infusion requirements with defasciculating doses of pancuronium. 

Anesth Analg 1997; 84: 668-71. 

348. Kim KS, Shim JC, Kim DW. Interactions between mivacurium and pancuronium. Br J Anaesth 1997; 79: 19-23. 

349. Motamed C, Menad R, Farinotti R, Kirov K, Combes X, Bouleau D, Feiss P, Duvaldestin P. Potentiation of mivacurium blockade by 

low dose of pancuronium: a pharmacokinetic study. Anesthesiology 2003; 98: 1057-62. 

350. Alderdice MT, Trommer BA. Differential effects of the anticonvulsants phenobarbital, ethosuximide and carbamazepine on 

neuromuscular transmission. J Pharmacol Exp Ther 1980; 215: 92-6. 

351. Roth S, Ebrahim ZY. Resistance to pancuronium in patients receiving carbamazepine. Anesthesiology 1987; 66: 691-3. 

352. Alloul K, Whalley DG, Shutway F, Ebraim Z, Varin FK. Pharmacokinetic origin of carbamazepine-induced resisance to vecuronium 

neuromuscular blockade in anesthetized patients. Anesthesiology 1996; 84: 330-9. 

353. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334: 168-75. 

354. Ornstein E, Matteo RS, Schwartz AE, Silverberg PA, Young WL, Diaz J. The effect of phenytoin on the magnitude and duration of 

neuromuscular blockade following atracurium or vecuronium. Anesthesiology 1987; 67: 191-6. 

355. Hickey DR, Sangwan S, Bevan JC. Phenytoin-induced resistance to pancuronium. Anesthesia 1988; 43: 757-9. 

356. Tempelhoff R, Modica PA, Jellish WS, Spitznagel EL. Resistance to atracurium-induced neuromuscular blockade in patients with 

intractable seizure disorders treated with anticonvulsants. Anesth Analg 1990; 71: 665-9. 

357. Kim CS, Ardnold FJ, Itani MS, Martyn JA. Decreased sensitivity to metocurine during long-term phenytoin therapy may be attributable 

to protein binding and acetylcholine receptor changes. Anesthesiology 1992; 77: 500-6. 

358. Jellish WS, Modica PA, Tempelhoff R. Accelerated recovery from pipecuronium in patients treated with chronic anticonvulsant therapy. 

J Clin Anesth 1993; 5: 105-8. 

359. Hans P, Ledoux D, Bonhomme V, Brichant JF. Effect of plasma anticonvulsant level on pipecuronium-induced neuromuscular blockade: 

preliminary results. J Neurosurg Anesthesiol 1995; 7: 254-8. 

360. Jellish WS, Thalji Z, Brundidge PK, Tempelhoff R. Recovery from mivacurium-induced neuromuscular blockade is not affected by 

anticonvulsant therapy. J Neurosurg Anesthesiol 1996; 8: 4-8. 

361. Spacek A, Neiger FX, Spiss CK, Kress HG. Atracurium-induced neuromuscular block is not affected by chronic anticonvulsant therapy 

with carbamazepine. Acta Anesthesiol Scand 1997; 41: 1308-11. 

362. Koenig HM, Hoffman WE. The effect of anticonvulsant therapy on two doses of rocuronium-induced neuromuscular blockade. J 

Neurosurg Anesthesiol 1999; 2: 86-9. 

363. Spacek A, Neiger FX, Krenn CG, Hoerauf K, Kress HG. Rocuronium-induced neuromuscular block is affected by chronic carbamazepine 

therapy. Anesthesiology 1999; 90: 109-12. 

364. Soriano SG, Kaus SJ, Sullivan LJ, Martyn JA. Onset and duration of action of rocuronium in children receiving chronic anticonvulsant 

therapy. Paediatr Anaesth 2000; 10: 133-6. 

365. Hernandez-Palazón J, Tortosa JA, Martinez-Lage JF, Pérez-Ayala M. Rocuronium-induce neuromuscular blockade is affected by chronic 

phenytoin therapy. J Neurosurg Anesthesiol 2001; 13: 79-82. 

366. Koenig HM, Edwards TL. Cis-atracurium-induced neuromuscular blockade in anticonvulsant treated neurosurgical patients. J Neurosurg 

Anesthesiol 2000; 12: 314-8. 

367. Soriano SG, Sullivan LJ, Venkatakrishnan K, Greenblatt DJ, Martyn JA. Pharmacokinetics and pharmacodynamics of vecuronium in 

children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. Br J Anaesth 2001; 86: 223-9. 

368. Richard A, Girard F, Girard DC, Boudreault D, Chouinard P, Moumdjian R, et al. Cisatracurium-induced neuromuscular blockade is 

affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. Anesth Analg 2005; 100: 538-44. 

369. Nguyen A, Ramzan I. Acute in vitro neuromuscular effects of carbamazepine and carbamazepine-10,11-epoxide. Anesth Analg 1997; 

84: 886-90. 

370. Whalley DG, Ebrahim Z. Influence of carbamazepine on the dose-response relationship of vecuronium. Br J Anaesth 1994; 72: 

125-6. 

371. Melton AT, Antognini J, Gronert GA. Prolonged duration of succinylcholine in patients receiving anticonvulsants: evidence of mild 

up-regulation of acetylcholine receptors? Can J Anaesth 1993; 40: 939-42. 

372. Gray HS, Slater RM, Pollard BJ. The effect of acutely administered phenytoin on vecuronium-induced neuromuscular blockade. 


373. Baumgardner JE, Bagshaw R. Acute versus chronic phenytoin therapy and neuromuscular blockade. Anaesthesia 1990; 45:493-4. 

374. Platt PR, Thackray NM. Phenytoin-induced resistance to vecuronium. Anaesth Intensive Care 1993; 21: 185-91. 

375. Braga Ade F, de Barcelos CC, Braga FS, Fernandes SC, Franco YO, Mantovani M, et al. Phenobarbital influence on neuromuscular block 

54



produced by rocuronium in rats. Acta Cir Bras 2008; 23: 343-7. 

376. Herrero E, Fernández-Guisasola J, García del Valle S. [Vecuronium resistance induced by chronic phenobarbital treatment]. Rev Esp 

Anestesiol Reanim 1996; 43: 113-4. 

377. Driessen JJ, Robertson EN, Booij LH, Vree TB. Accelerated recovery and disposition from rocuronium in an end-stage renal failure 

patient on chronic anticonvulsant therapy with sodium valproate and primidone. Br J Anaesth 1998; 80: 386-8. 

378. Nguyen A, Ramzan I. In vitro neuromuscular effects of valproic acid. Br J Anaesth 1997; 78: 197-200. 

379. Blanc-Bimar MC, Jadot G, Bruguerolle B, Valli M, Bouyard P. [Modification of curarization after acute administration of 2 antiepileptic 

drugs]. Ann Anesthesiol Fr 1979; 20: 685-90. 

380. Alkadhi KA, Banks FW. Pre- and postsynaptic actions of valproic acid at the frog neuromuscular junction. Brain Res 1984; 306: 

388-90. 

381. Chea LS, Lee SH, Gwee MCE. Anticholinesterase activity of and possible ion-channel block by cimetidine, ranitidine and oxymetidine 

in the toad isolated rectus abdominis muscle. Clin Exp Pharmacol Physiol 1985; 12: 353-7. 

382. Lee HS, Chea LS, Gwee MCE. Inhibition of acetylcholinesterase by histamine agonists and antagonists. Clin Exp Pharmacol Physiol 

1985; 12: 613-20. 

383. Gwee MCE, Cheah LS, Shoon ML. Cimetidine and ranitidine: a study of competitive and ion-channel blockade in the toad isolated 

rectus abdominis muscle. Clin Exp Pharmacol Physiol 1986; 13: 613-8. 

384. Jensen JC, Gugler R. Relevant inhibition of acetylcholinesterase with H 2-receptor antagonists. Z Gastroenterol 1984; 22: 109-12. 

385. Kambam JR, Franks JJ. Cimetidine does not affect plasma cholinesterase activity. Anesth Analg 1988; 67: 64-8. 

386. Law SC, Ramzan IM, Brandom BW, Cook DR. Intravenous ranitidine antagonizes intense atracurium-induced neuromuscular blockade 

in rats. Anesth Analg 1989; 69: 611-3. 

387. Kambam JR, Dymond R, Krestow M. Effect of cimetidine on duration of action of succinylcholine. Anesth Analg 1987; 66: 191-2. 

388. Stirt JA, Sperry RJ, DiFazio CA. Cimetidine and succinylcholine: potential interaction and effect on neuromuscular blockade in man. 


389. Woodworth GE, Sears DH, Grove TM, RuffRH, Kosek PS, Katz RL. The effect of cimetidine and ranitidine on the duration of action 

of succinylcholine. Anesth Analg 1989; 68: 295-7. 

390. Mishra Y, Ramzan I. Interaction between succinylcholine and cimetidine in rats. Can J Anaesth 1992; 39: 370-64. 

391. Mishra Y, Ramzan I. Influence of cimetidine on gallamine-induced neuromuscular paralysis in rats. Clin Exp Pharmacol Physiol 1992; 

19: 803-7. 

392. Mishra Y, Ramzan I. Ranitidine reverses gallamine paralysis in rats. Anesth Analg 1993; 76: 627-30. 

393. Fuchs-Buder T, Tassonyi E. Magnesium sulphate enhances residual neuromuscular block induced by vecuronium. Br J Anaesth 1996; 

76: 565-566. 

394. Ahn EK, Bai SJ, Cho BJ, Shin YS. The infusion rate of mivacurium and its spontaneous neuromuscular recovery in magnesium-treated 

parturients. Anesth Analg 1998; 86: 523-6. 

395. Fawcett WJ, Stone JP. Recurarization in the recovery room following the use of magnesium sulphate. Br J Anaesth 2003; 91: 435-8. 

396. Pinard AM, Donati F, Martineau R, Denault AY, Taillefer J, Carrier M. Magnesium potentiates neuromuscular blockade with 

cisatracurium during cardiac surgery. Can J Anaesth 2003; 50: 172-8. 

397. Olivieri L, Plourde G. Prolonged (more than ten hours) neuromuscular blockade after cardiac surgery: report of two cases. Can J Anaesth 

2005; 52: 88-93. 

398. Kussman B, Shorten G, Uppington J, Comunale ME. Administration of magnesium sulphate before rocuronium: effects on speed of 

onset and duration of neuromuscular block. Br J Anaesth 1997; 79: 122-4. 

399. Hodgson RE, Rout CC, Rocke DA, Louw NJ. Mivacurium for caesarean section in hypertensive parturients receiving magnesium 

sulphate therapy. Int J Obstet Anesth 1998; 7: 12-17. 

400. Tsal SK, Huang SW, Lee TY. Neuromuscular interactions between suxamethonium and magnesium sulphate in the cat. Br J Anaest 

1994; 72: 674-8. 

401. Cairoli VJ, Ivankovich AD, Vucicevic D, Patel K. Succinylcholine-induced hyperkalemia in the rat following radiation injury to muscle. 

Anesth Analg 1982; 61: 83-6. 

402. Holak EJ, Connelly JF, Pagel PS. Suxamethonium-induced hyperkalaemia 6 weeks after chemoradiotherapy in a patient with rectal 

carcinoma. Br J Anaesth 2007; 98: 766-8. 

403. Al-Khafaji AH, Dewhirst WE, Cornell CJ Jr, Quill TJ. Succinylcholine-induced hyperkalemia in a patient with mucositis secondary to 

chemotherapy. Crit Care Med 2001; 29: 1274-6. 

404. Bradamante V, Smigovec E, Buković D, Geber J, Matanić D. Plasma cholinesterase activity in patients with uterine cervical cancer 

during radiotherapy. Coll Antropol 2000; 24: 373-80. 

405. Belfrage P, Schildt B. Increased sensitivity to the muscle-relaxing effect of succinylcholine in irradiated rabbits. Acta Anaesthesiol Scand 

1967; 11: 65-75. 

406. Martyn JA, White DA, Gronert GA, Jaffe RS, Ward JM. Up- and down-regulation of skeletal muscle acetylcholine receptors. Effects on 

neuromuscular blockers. Anesthesiology 1992; 76: 822-43. 

55



407. Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular 

mechanisms. Anesthesiology 2006; 104: 158-69. 

408. Hogue CW Jr, Itani MS, Martyn JA. Resistance to d-tubocurarine in lower motor neuron injury is related to increased acetylcholine 

receptors at the neuromuscular junction. Anesthesiology 1990; 73: 703-9. 

409. Shuetze SM, Role LW. Development regulation of nicotinic acetylcholine receptors. Annu Rev Neurosci 1987; 10: 403-57. 

410. Hunter JM, Bell CF, Florence AM, Jones RS, Utting JE. Vecuronium in the myasthenic patient. Anaesthesia 1985; 40: 848-53. 

411. Baraka AS, Taha SK, Kawkabani NI. Neuromuscular interaction of sevoflurane--cisatracurium in a myasthenic patient. Can J Anaesth 

2000; 47: 562-5. 

412. De Haes A, Proost JH, De Baets MH, Stassen MH, Houwertjes MC, Wierda JM. Decreased number of acetylcholine receptors is the 

mechanism that alters the time course of muscle relaxants in myasthenia gravis: a study in a rat model. Eur J Anaesthesiol 2005; 22: 

591-6. 

413. De Haes A, Proost JH, Kuks JB, van den Tol JC, Wierda JMKH. Pharmacokinetic/pharmacodynamic modeling of rocuronium in 

myasthenic patients is improved by taking into account the number of unbound acetylcholine receptors. Anesth Analg 2002; 95: 

588-96. 

414. Itoh H, Shibata K, Nitta S. Difference in sensitivity to vecuronium between patients with ocular and generalized myasthenia gravis. Br 

J Anaesth 2001; 87: 885-9. 

415. Ward S, Wright DJ. Neuromuscular blockade in myasthenia gravis with atracurium besylate. Anaesthesia 1984; 39: 51-3. 

416. Bell CF, Florence AM, Hunter JM, Jones RS, Utting JE. Atracurium in the myasthenic patient. Anaesthesia 1984; 39: 961-8. 

417. Vacanti CA, Ali HH, Schweiss JF, Scott RP. The response of myasthenia gravis to atracurium. Anesthesiology 1985; 62: 692-4. 

418. Paterson IG, Hood JR, Russell SH, Weston MD, Hirsch NP. Mivacurium in the myasthenic patient. Br J Anaesth 1994; 73: 494-8. 

419. Baraka A. Suxamethonium block in the myasthenic patient. Correlation with plasma cholinesterase. Anaesthesia 1992; 47: 217-9. 

420. Baraka A, Baroody M, Yazbeck V. Repeated doses of suxamethonium in the myasthenic patient. Anaesthesia 1993; 48: 782-4. 

421. Tobias DT, Atwood R. Mivacurium in children with Duchenne muscular dystrophy. Pediatr Anesth 1994; 4: 57-60. 

422. Ririe DG, Shapiro F, Sethna NF. The response of patients with Duchenne’s muscular dystrophy to neuromuscular blockade with 

vecuronium. Anesthesiology 1998; 88: 351-4. 

423. Uslu M, Mellinghoff H, Diefenbach C. Mivacurium for muscle relaxation in a child with Duchenne’s muscular dystrophy. Anesth Analg 

1999; 89: 340-1. 

424. Schmidt J, Muenster T, Wick S, Forst J, Schmitt HJ. Onset and duration of mivacurium-induced neuromuscular blockade in patients 

with Duchenne muscular dystrophy. Br J Anaesth 2005; 95: 769-72. 

425. Wick S, Muenster T, Schmidt J, Forst J, Schmitt HJ. Onset and duration of rocuronium-induced neuromuscular blockade in patients 

with Duchenne muscular dystrophy. Anesthesiology 2005; 102: 915-9. 

426. Muenster T, Schmidt J, Wick S, Forst J, Schmitt HJ. Rocuronium 0.3 mg x kg-1 (ED95) induces a normal peak effect but an altered time 

course of neuromuscular block in patients with Duchenne’s muscular dystrophy. Paediatr Anaesth 2006; 16: 840-5. 

427. Caron MJ, Girard F, Girard DC, Boudreault D, Brais B, Nassif E, et al. Cisatracurium pharmacodynamics in patients with oculopharyngeal 

muscular dystrophy. Anesth Analg 2005; 100: 393-7. 

428. Buzello W, Huttarsch H. Muscle relaxation in patients with Duchenne’s muscular dystrophy. Use of vecuronium in two patients. Br J 

Anaesth 1988; 60: 228-31. 

429. Landrum AL, Eggers CWN. Oculopharyngeal dystrophy: an approach to anesthetic management. Anesth Analg 1992; 75: 1043-5. 

430. Chun R. Safe use of mivacurium in oculopharyngeal muscular dystrophy. Can J Anaesth 1998; 45: 1134. 

431. Ihmsen H, Viethen V, Forst J, Schwilden H, Schmitt HJ, Muenster T. Pharmacodynamic modelling of rocuronium in adolescents with 

Duchenne muscular dystrophy. Eur J Anaesthesiol 2009; 26: 105-10. 

432. Dresner DL, Ali HH. Anaesthetic management of a patient with facioscapulohumeral muscular dystrophy. Br J Anaesth 1989; 62: 

331-4. 

433. Nitahara K, Sakuragi T, Matsuyama M, Dan K. Response to vecuronium in a patient with facioscapulohumeral muscular dystrophy. 

Br J Anaesth 1999; 83: 499-500. 

434. Mitchell MM, Ali HH, Savarese JJ. Myotonia and neuromuscular blocking agents. Anesthesiology 1978; 49: 44-8. 

435. Azar I. The response of patients with neuromuscular disorders to muscle relaxants: a review. Anesthesiology 1984; 61: 173-87. 

436. Kennedy F, Wolf A. Experiments with quinine and prostigmine in the treatment of myotonia and myasthenia. Arch Neural Psych 1937; 

37: 68-73. 

437. Paterson IS. Generalized myotonia following suxamethonium. A case report. Br J Anaesth 1962; 34: 340-2. 

438. Ravin N, Newmark Z, Saviello G. Myotonia dystrophica, an anasthetic hazard: two case. Reports Anesthesia and Analgesia 1975; 54: 

216-8. 

439. Pollard BJ, Young TM. Anaesthesia in myotonia dystrophica. Anasthesia 1989; 44: 699. 

440. Blumgart CH, Hughes DG, Redfern N. Obstetric anasthesia in dystrophia myotonica. Anasthesia 1990; 45: 26-9. 

441. Nightingale P, Healy TE, McGuinness K. Dystrophia myotonica and atracurium. A case report. Br J Anaesth 1985; 57: 1131-5. 

56



442. Stirt JA, Stone DJ, Weinberg G, Willson DF, Sternick CS, Sussman MD. Atracurium in a child with myotonic dystrophy. Anesth Analg 

1985; 64: 369-70. 

443. Boheimer N, Harris JW, Ward S. Neuromuscular blockade in dystrophia mytonica. Anaesthesia 1985; 40: 872-4. 

444. White DA, Smyth DG. Continuous infusion of propofol in dystrophia myotonica. Can J Anaesth 1989; 36: 200-3. 

445. Jenkins JA, Facer EK. Anesthetic management of a patient with myotonic dystrophy for a Nissen fundoplication and gastrostomy. 

Pediatric Anesthesia 2004; 14: 693-6. 

446. Watt NA, Scott RP. Mivacurium chloride and myotonic dystrophy. Br J Anaesth 1995; 75: 498-9. 

447. Castano J, Pares N. Anaesthesia for major abdominal surgery in a patient with myotonia dystrophica. Br J Anaesth 1987; 59: 1629-31. 

448. Wruck G, Tryba M. [Vecuronium in dystrophia myotonica (Curschmann-Steinert)]. Anaesthesist 1989; 38: 255-8. 

449. Diefenbach C, Lynch J, Abel M, Buzello W. Vecuronium forcmuscle relaxation in patients with dystrophia myotonica. Anesthesia and 

Analgesia 1993; 76: 872-4. 

450. Nishi M, Itoh H, Tsubokawa T, Taniguchi T, Yamamoto K. Effective doses of vecuronium in a patient with myotonic dystrophy. 


451. Russell SH, Hirsch NP. Anaesthesia and myotonia. Br J Anaesth 1994; 72: 210-6. 

452. Wiesel S, BevanJC, Samuel J, Donati F. Vecuronium neuromuscular blockade in a child with mitochondrial myopathy. Anesth Analg 

1991; 72: 696-9. 

453. Naguib M, El Dawlatly AA, Ashour M, Al-Bunyan M. Sensitivity to mivacurium in a patient with mitochondrial myopathy. Anesthesiology 

1996; 84: 1506-9. 

454. Finsterer J, Stratil U, Bittner R, Sporn P. Increased sensitivity to rocuronium and atracurium in mitochondrial myopathy. Can J Anaesth 

1998; 45: 781-4. 

455. Wisely NA, Cook PR. General anaesthesia in a man with mitochondrial myopathy undergoing eye surgery. Eur J Anaesthesiol 2001; 

18: 333-5. 

456. Klockgether-Radke A, Henze T, Braun U, Kettler D. Anesthesia in two patients with mitochondrial myopathy. Anaesthesist 1993; 42: 

111-4. 

457. Thompson VA, Wahr JA. Anesthetic considerations in patients presenting with mitochondrial myopathy, encephalopathy, lactic acidosis, 

and stroke-like episodes (MELAS) syndrome. Anesth Analg 1997; 85: 1404-6. 

458. Ciccotelli KK, Prak EL, Muravchick S. An adult with inherited mitochondrial encephalomyopathy: report of a case. Anesthesiology 

1997; 87: 1240-2. 

459. Aouad MT, Gerges FJ, Baraka AS. Resistance to cisatracurium in a patient with MELAS syndrome. Paediatr Anaesth 2005; 15: 

1124-7. 

460. Martyn JAJ, White DA, Gronert GA, Jaffe RS, Ward JM. Up-and-down regulation of skeletal muscle acetylcholine receptors: Effects on 

neuromuscular blockers. Anesthesiology 1992; 76: 822-43. 

461. Gronert GA, Lambert EH, Theye RA. The response of denervated skeletal muscle to succinylcholine. Anesthesiology 1973; 39: 13-22. 

462. Hogue CW Jr, Itani MS, Martyn JA. Resistance to d-tubocurarine in lower motor neuron injury is related to increased acetylcholine 

receptors at the neuromuscular junction. Anesthesiology 1990; 73: 703-9. 

463. Graham DH. Monitoring neuromuscular block may be unreliable in patients with upper motor-neuron lesions. Anesthesiology 1980; 

52: 74-5. 

464. Moorthy SS, Hilgenberg JC. Resistance to non-depolarizing muscle relaxants in paretic upper extremities of patients with residual 

hemiplegia. Anesth Analg 1980; 59: 624-7. 

465. Shayevitz JR, Matteo RS. Decreased sensitivity to metocurine in patients with upper motoneuron disease. Anesth Analg 1985; 64: 

767-72. 

466. Baraka AS, Jalbout MI. Anesthesia and myopathy. Curr Opin Anaesthesiol 2002; 15: 371-6. 

467. Hara K, Minami K, Takamato K, Shiraishi M, Sata T. The prolonged effect of a muscle relaxant in a patient with chronic inflammatory 

demyelinating polyradiculoneuropathy. Anesth Analg 2000; 90: 224-6. 

468. Fink H, Bogdanski R, Luppa P, Martyn JA, Blobner M. Nitric oxide is not a mediator of inflammation-induced resistance to atracurium. 

Anesth Analg 2005; 101: 1362-7. 

469. Fink H, Luppa P, Mayer B, Rosenbrock H, Metzger J, Martyn JA, Blobner M. Systemic inflammation leads to resistance to atracurium 

without increasing membrane expression of acetylcholine receptors. Anesthesiology 2003; 98: 82-8. 

470. Blobner M, Kochs E, Fink H, Veihelmann A, Brill T, Stadler J. Pharmacokinetics and pharmacodynamics of vecuronium in rats with 

systemic inflammatory response syndrome: treatment with NG-monomethyl-L-arginine. Anesthesiology 1999; 91: 999-1005. 

471. Narimatsu E, Nakayama Y, Sumita S, Iwasaki H, Fujimura N, Satoh K, et al. Sepsis attenuates the intensity of the neuromuscular blocking 

effect of d-tubocurarine and the antagonistic actions of neostigmine and edrophonium accompanying depression of muscle contractility 

of the diaphragm. Acta Anaesthesiol Scand 1999; 43: 196-201. 

472. Soltész S, Mencke T, Mey C, Röhrig S, Diefenbach C, Molter GP. Influence of a continuous prednisolone medication on the time course 

of neuromuscular block of atracurium in patients with chronic inflammatory bowel disease. Br J Anaesth 2008; 100: 798-802. 

473. Blanloeil Y, Delaroche O, Tequi B, Gunst JP, Dixneuf B. [Prolonged apnoe after administration of succinylcholine during staphylococcal 

57



shock]. Ann Fr Anesth Réanim 1996; 15: 189-91. 

474. Ward JM, Martyn JA. Burn injury-induced nicotinic acetylcholine receptor changes on muscle membrane. Muscle Nerve 1993; 16: 

348-54. 

475. Martyn JAJ, Fukushima Y, Chon JY, Yang HS. Muscle relaxants in burns, trauma, and critical illness. Int Anesthesiol Clin 2006; 44: 

123-43. 

476. Martyn JAJ, Liu LM, Szyfelbein SK, Ambalavanar ES, Goudsouzian NG. The neuromuscular effects of pancuronium in burned children. 


477. Dwersteg JF, Pavlin EG, Heimbach DM. Patients with burns are resistant to atracurium. Anesthesiology 1986; 65: 517-20. 

478. Mills AK, Martyn JA. Evaluation of atracurium neuromuscular blockade in paediatric patients with burn injury. Br J Anaesth 1988; 

60: 450-5. 

479. Marathe PH, Dwersteg JF, Pavlin EG, Haschke RH, Heimbach DM, Slattery JT. Effect of thermal injury on the pharmacokinetics and 

pharmacodynamics of atracurium in humans. Anesthesiology 1989; 70: 752-5. 

480. Mills AK, Martyn JAJ. Neuromuscular blockade with vecuronium in paediatric patients with burn injury. Br J Clin Pharmac 1989; 28: 

155-9. 

481. Coursin DB, Klasek G, Goelzer SL. Increased requirements for continuously infused vecuronium in critically ill patients. Anesth Analg 

1989; 69: 518-21. 

482. Han T, Kim H, Bae J, Kim K, Martyn JA. Neuromuscular pharmacodynamics of rocuronium in patients with major burns. Anesth 

Analg 2004; 99: 386-92. 

483. Werba AE, Neiger FX, Bayer GS, Schultz AM, Maitz PKM, Wolrab CH. Pharmacodynamics of mivacurium in severly burned patients. 

Burns 1996; 22: 62-4. 

484. Martyn JA, Goudsouzian NG, Chang Y, Szyfelbein SK, Schwartz AE, Patel SS. Neuromuscular effects of mivacurium in 2- to 12-yr-old 

children with burn injury. Anesthesiology 2000; 92: 31-7. 

485. Martyn JA, Chang Y, Goudsouzian NG, Patel SS. Pharmacodynamics of mivacurium chloride in 13- to 18-yr-old adolescents with 

thermal injury. Br J Anaesth 2002; 89: 580-5. 

486. Fung DL, White DA, Jones BR, Gronert GA. The onset of disuse-related potassium efflux to succinylcholine. Anesthesiology 1991; 75: 

650-3. 

487. Yanez P, Martyn JA. Prolonged d-tubocurarine infusion and/or immobilization cause upregulation of acetylcholine receptors and 

hyperkalemia to succinylcholine in rats. Anesthesiology 1996; 84: 348-91. 

488. Fink H, Helming M, Unterbuchner C, Lenz A, Neff F, Martyn JA, et al. Systemic inflammatory response syndrome increases immobilityinduced 

neuromuscular weakness. Crit Care Med 2008; 36: 910-6. 

489. Ibebunjo C, Nosek MT, Itani MS, Martyn JA. Mechanisms for the paradoxical resistance to d-tubocurarine during immobilizationinduced 

muscle atrophy. J Pharmacol Exp Ther 1997; 283: 443-51. 

490. Moorthy SS, Hilgenberg JC. Resistance to non-depolarizing muscle relaxants in paretic upper extremities of patients with residual 

hemiplegia. Anesth Analg 1980; 59: 624-7. 

491. Gronert GA. Disuse atrophy with resistance to pancuronium. Anesthesiology 1981; 55: 547-9. 

492. Hogue CW Jr, Ward JM, Itani MS, Martyn JA. Tolerance and upregulation of acetylcholine receptors follow chronic infusion of dtubocurarine. 

J Appl Physiol 1992; 72: 1326-31. 

493. Kim KS, Jeon JW, Koh MS, Shim JH, Cho SY, Suh JK. The duration of immobilization causes the changing pharmacodynamics of 

mivacurium and rocuronium in rabbits. Anesth Analg 2003; 96: 438-42. 

494. Fink H, Yasuhara S, Blobner M, Martyn JA. Up-regulation of acetylcholine receptors during subchronic infusion of pancuronium is 

caused by a posttranscriptional mechanism related to disuse. Crit Care Med 2004; 32: 509-13. 

495. Booij LH. Is succinylcholine appropriate or obsolete in the intensive care unit? Crit Care 2001; 5: 245-6. 

496. Fagiolino P, Eiraldi R, Vázquez M. The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/ 

pharmacodynamic relationships. Clin Pharmacokinet 2006; 45: 433-48. 

497. Muñoz HR, González AG, Dagnino JA, González JA, Pérez AE. The effect of ephedrine on the onset time of rocuronium. Anesth Analg 

1997; 85: 437-40. 

498. Albert F, Hans P, Bitar Y, Brichant JF, Dewandre PY, Lamy M. Effects of ephedrine on the onset time of neuromuscular block and 

intubating conditions after cisatracurium: preliminary results. Acta Anaesthesiol Belg 2000; 51: 167-71. 

499. Kim KS, Cheong MA, Jeon JW, Lee JH, Shim JC. The dose effect of ephedrine on the onset time of vecuronium. Anesth Analg 2003; 96: 

1042-6. 

500. Ganidagli S, Cengiz M, Baysal Z. Effect of ephedrine on the onset time of succinylcholine. Acta Anaesthesiol Scand 2004; 48: 1306-9. 

501. Han DW, Chun DH, Kweon TD, Shin YS, Han DW, Chun DH, et al. Anaesthesia 2008; 63: 856-60. 

502. Wang YG, Song XJ, Feng SW, Ge YL, Yang JJ, He LL. Hyperthyroidism patients have shorter onset and duration time of rocuronium 

than euthyroidism patients. J Pharm Pharm Sci 2007; 10: 53-60. 

503. Szmuk P, Ezri T, Chelly JE, Katz J. The onset time of rocuronium is slowed by esmolol and accelerated by ephedrine. Anesth Analg 2000; 

90: 1217-9. 

58



504. Ezri T, Szmuk P, Warters RD, Gebhard RE, Pivalizza EG, Katz J. Changes in onset time of rocuronium in patients pretreated with 

ephedrine and esmolol--the role of cardiac output. Acta Anaesthesiol Scand 2003; 47: 1067-72. 

505. Aziz L, Ono K, Ohta Y, Morita K, Hirakawa M. The effect of CO 2-induced acid-base changes on the potencies of muscle relaxants and 

antagonism of neuromuscular block by neostigmine in rat in vitro. Anesth Analg 1994; 78: 322-7. 

506. Crul-Sluijter EJ, Crul JF. Acidosis and neuromuscular blockade. Acta Anaesthesiol Scand 1974; 18: 224-36. 

507. Funk DI, Crul JF, Pol FM. Effects of changes in acid-base balance on neuromuscular blockade produced by ORG-NC 45. Acta Anaesthesiol 

Scand 1980; 24: 119-24. 

508. Hughes R, Chapple DJ. The pharmacology of atracurium: a new competitive neuromuscular blocking agent. Br J Anaesth 1981; 53: 

31-44. 

509. Gencarelli PJ, Swen J, Koot HW, Miller RD. The effects of hypercarbia and hypocarbia on pancuronium and vecuronium neuromuscular 

blockades in anesthetized humans. Anesthesiology 1983; 59: 376-80. 

510. Biró K. Effects of respiratory and metabolic alkalosis and acidosis on pipecuronium neuromuscular block. Eur J Pharmacol 1988; 154: 

329-33. 

511. Yamauchi M, Takahashi H, Iwasaki H, Namiki A. Respiratory acidosis prolongs, while alkalosis shortens, the duration and recovery 

time of vecuronium in humans. J Clin Anesth 2002; 14: 98-101. 

512. Payne JP. The influence of changes in blood pH on the neuromuscular blocking properties of tubocurarine and dimethyl tubocurarine 

in the cat. Acta Anaesthesiol Scand 1960; 4: 83-90. 

513. Hughes R. The influence of changes in acid-base balance on neuromuscular blockade in cats. Br J Anaesth 1970; 42: 658-68. 

514. Ono K, Ohta Y, Morita K, Kosaka F. The influence of respiratory-induced acid-base changes on the action of non-depolarizing muscle 

relaxants in rats. Anesthesiology 1988; 68: 357-62. 

515. Ono K, Nagano O, Ohta Y, Kosaka F. Neuromuscular effects of respiratory and metabolic acid-base changes in vitro with and without 

nondepolarizing muscle relaxants. Anesthesiology 1990; 73: 710-6. 

516. Miller RD, Roderick LL. Acid-base balance and neostigmine antagonism of pancuronium neuromuscular blockade. Br J Anaesth 1978; 

50: 317-24. 

517. Eriksson LI, Viby-Mogensen J, Lennmarken C. The effect of peripheral hypothermia on a vecuronium-induced neuromuscular block. 

Acted Anaesthesiol Scand 1991; 35: 387-92. 

518. Suzuki T, Kitajima O, Watanabe A, Nonaka H, Saeki S, Ogawa S. Duration of vecuronium-induced neuromuscular block can be predicted 

by change of skin temperature over the thenar muscles. J Anesth 2004; 18: 172-6. 

519. Heier T, Caldwell JE. Impact of hypotrhermia on the response to neuromuscular blocking drugs. Anesthesiology 2006; 194: 1070-80. 

520. Avram MJ, Shanks CA, Henthorn TK, Ronai AK, Kinzer J, Wilkinson CJ. Metocurine kinetics in patients undergoing operations 

requiring cardiopulmonary bypass. Clin Pharmacol Ther 1987; 42: 571-81. 

521. Flynn PJ, Hughes R, Walton B. Use of atracurium in cardiac surgery involving cardiopulmonary bypass with induced hypothermia. 

Br J Anaesth 1984; 56: 967-72. 

522. Denny NM, Kneeshaw JD. Vecuronium and atracurium infusions during hypothermic cardiopulmonary bypass. Anaesthesia 1986; 

41: 919-22. 

523. Diefenbach C, Abel M, Buzello W. Greater neuromuscular blocking potency of atracurium during hypothermic than during normothermic 

cardiopulmonary bypass. Anesth Analg 1992; 75: 675-8. 

524. Leslie K, Sessler DI, Bjorksten AR, Moayeri A. Mild hypothermia alters propofol pharmacokinetics and increases the duration of action 

of atracurium. Anesth Analg 1995; 80: 1007-14. 

525. Playfor SD, Thomas DA, Choonara I. The effect of induced hypothermia on the duration of action of atracurium when given by infusion 

to critically ill children. Paediatr Anaesth 2000; 10: 83-8. 

526. Meyer RE, Page RL, Thrall DE, Dewhirst MW, Vose DL. Determination of continuous atracurium infusion rate in dogs undergoing 

whole-body hyperthermia. Cancer Res 1986; 46: 5599-601. 

527. Cammu G, Coddens J, Hendrickx J, Deloof T. Dose requirements of infusions of cisatracurium or rocuronium during hypothermic 

cardiopulmonary bypass. Br J Anaesth 2000; 84: 587-90. 

528. Park WY, Macnamara TE. Temperature change and neuromuscular blockade by d-tubocurarine or pancuronium in man. Anesthesiology 

1979; 50: 161-3. 

529. Miller RD, Agoston S, van der Pol F, Booij LH, Crul JF, Ham J. Hypothermia and the pharmacokinetics and pharmacodynamics of 

pancuronium in the cat. J Pharmacol Exp Ther 1978; 207: 532-8. 

530. Futter ME, Whalley DG, Wynands JE, Bevan DR. Pancuronium requirements during hypothermic cardiopulmonary bypass in man. 

Anaesth Intensive Care 1983; 11: 216-9. 

531. Buzello W, Schluermann D, Schindler M, Spillner G. Hypothermic cardiopulmonary bypass and neuromuscular blockade by 

pancuronium and vecuronium Anesthesiology 1985; 62: 201-4. 

532. Buzello W, Schluermann D, Pollmaecher T, Spillner G. Unequal effects of cardiopulmonary bypass-induced hypothermia on 

neuromuscular blockade from constant infusion of alcuronium, d-tubocurarine, pancuronium, and vecuronium. Anesthesiology 1987; 

66: 842-6. 

59



533. Heier T, Caldwell JE, Sessler DI, Miller RD. Mild intraoperative hypothermia increases duration of action and spontaneous recovery 

of vecuronium blockade during nitrous oxide-isoflurane anesthesia in humans. Anesthesiology 1991; 74: 815-9. 

534. Caldwell JE, Heier T, Wright PM, Lin S, McCarthy G, Szenohradszky J, et al. Temperature-dependent pharmacokinetics and 

pharmacodynamics of vecuronium. Anesthesiology 2000; 92: 84-93. 

535. Mol WEM, Fokkema GN, Weert B, Meijer DKF. Mechanisms for the hepatic uptake of organic cations: Studies with the muscle relaxant 

vecuronium. In isolated rat hepatocytes. J Pharmacol Exp Ther 1988; 244: 268-75. 

536. Beaufort TM, Proost JH, Maring J, Scheffer ER, Wierda JK, Meijer DK. Effect of hypothermia on the hepatic uptake and biliary excretion 

of vecuronium in the isolated perfused rat liver. Anesthesiology 2001; 94: 270-9. 

537. Adachi T, Shinomura T, Nomura R. Duration of vecuronium-induced neuromuscular blockade is shortened during hyperthermic 

intraoperative intraperitoneal chemotherapy. Br J Anaesth 2003; 91: 160-1. 

538. Beaufort AM, Wierda JM, Belopavlovic M, Nederveen PJ, Kleef UW, Agoston S. The influence of hypothermia (surface cooling) on the 

time-course of action and on the pharmacokinetics of rocuronium in humans. Eur J Anaesthesiol Suppl 1995; 11: 95-106. 

539. Smeulers NJ, Wierda JM, van den Broek L, Gallandat Huet RC, Hennis PJ. Hypothermic cardiopulmonary bypass influences the 

concentration-response relationship and the biodisposition of rocuronium. J Cardiothorac Vasc Anesth 1995; 9: 700-5. 

540. Aziz L, Ono K, Ohta Y, Morita K, Hirakawa M. Effect of hypothermia on the in vitro potencies of neuromuscular blocking agents and 

on their antagonism by neostigmine. Br J Anaesth 1994; 73: 662-6. 

541. Roy JJ, Varin F. Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic 

relationship. Br J Anaesth 2004; 93: 241-8. 

542. Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-l-acid glycoprotein in health and disease. Pharmacol Rev 1988; 

40: 1-47. 

543. García E, Calvo R, Rodríguez-Sasiaín JM, Jiménez R, Trocóniz IF, Suárez E. Resistance to atracurium in rats with experimental 

inflammation: role of protein binding. Acta Anaesthesiol Scand 1995; 39: 1019-23. 

544. Wood M, Wood AJJ. Changes in plasma drug binding and alpha,-acid glycoprotein in mother and newborn infant. Clin Pharmacol 

Ther 1981; 29: 522-6. 

545. Tatman AJ, Wrigley SR, Jones RM. Resistance to atracurium in a patient with an increase in plasma alpha 1 globulins. Br J Anaesth 

1991; 67: 623-5. 

546. Foldes FF, Deery A. Protein binding of atracurium and other short-acting neuromuscular blocking agents and their interaction with 

human cholinesterases. Br J Anaesth 1983; 55 Suppl 1: 31S-34S. 

547. Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, et al. Residual neuromuscular block is a risk factor for 

postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications 

after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41: 1095–103. 

548. Eriksson LI. Residual neuromuscular blockade. Incidence and relevance. Anaesthetist 2000; 49 (Suppl. 1): 518-9. 

549. Lunn JN, Hunter AR, Scott DB. Anaesthesia-related surgical mortality. Anaesthesia 1983; 38: 1090-6. 

550. Tiret L, Desmonts JM, Hatton F, Vourc’h G. Complications associated with Anaesthesia – a prospective survey in France. Can Anaesth 

Soc J 1986; 33: 336-44. 

551. Cooper AL, Leigh JM, Tring IC. Admissions to the intensive care unit after complications of Anaesthetic techniques over 10 years. 1. 

The first 5 years. Anaesthesia 1989; 44: 953-8. 

552. Eriksson LI, Lennmarken C, Wyon N, Johnson A. Attenuated ventilatory response to hypoxaemia at vecuronium-induced partial 

neuromuscular block. Acta Anaesthesiol Scand 1992; 36: 710-5. 

553. Eriksson LI, Sato M, Severinghaus JW. Effect of a vecuroniuminduced partial neuromuscular block on hypoxic ventilatory response. 


554. Eriksson LI, Sundman E, Olsson R, Nilsson L, Witt H, Ekberg O, et al. Functional assessment of the pharynx at rest and during swallowing 

in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology 

1997; 87: 1035-43. 

555. Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper 

esophageal dysfunction in partially paralyzed humans. Pharyngeal videoradiography and simultaneous manometry after atracurium. 


556. Eikermann M, Blobner M, Groeben H, Rex C, Grote T, Neuhäuser M, et al. Postoperative upper airway obstruction after recovery of 

the train of four ratio of the adductor pollicis muscle from neuromuscular blockade. Anesth Analg 2006; 102: 937-42. 

557. Viby-Mogensen J, Jørgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology 1979; 50: 539-41. 

558. Lennmarken C, Löfström JB. Partial curarization in the postoperative period. Acta Anaesthesiol Scand 1984; 28: 260-2. 

559. Howardy-Hansen P, Rasmussen JA, Jensen BN. Residual curarization in the recovery room: atracurium versus gallamine. Acta 


560. Viby-Mogensen J. Postoperative residual curarization and evidence-based anaesthesia. Br J Anaesth 2000; 84: 301-3. 

561. Debaene B, Plaud B, Dilly M, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant 

with an intermediate duration of action. Anesthesiology 2003; 98: 1042-8. 

60



562. Murphy GS, Szokol JW, Marymont JH, Franklin M, Avram MJ, Vender JS. Residual paralysis at the time of tracheal extubation. Anesth 

Analg 2005; 100: 1840-5. 

563. Beaussier M, Boughaba MA. Curarisation résiduelle. Ann Fr Anesth Réanim 2005; 24: 10. 

564. McCaul C, Tobin E, Boylan JF, McShane AJ. Atracurium is associated with postoperative residual curarization. Br J Anaesth 2002; 89: 

766-9. 

565. Cammu G, de Baerdemaeker L, den Blauwen N, de Mey JC, Struys M, Mortier E. Postoperative residual curarization with cisatracurium 

and rocuronium infusions. Eur J Anaesthesiol 2002; 19: 129-34. 

566. Murphy GS, Szokol JW, Marymont JH, Vender JS, Avram MJ, Rosengart TK, et al. Recovery of neuromuscular function after cardiac 

surgery: pancuronium versus rocuronium. Anesth Analg 2003; 96: 1301-7. 

567. Baillard C, Gehan G, Reboul-Marty J, Larmignat P, Samama C, Cupa M. Residual curarization in the recovery room after vecuronium. 

Br J Anaesth 2000; 84: 394-5. 

568. Hayes AH, Mirakhur RK, Breslin DS, Reid JE, McCourt KC. Postoperative residual block after intermediate-acting neuromuscular 

blocking drugs. Anaesthesia 2001; 56: 31. 

61

Variability in the effect of muscle relaxants Factors - Anestezjologia i ...

Create successful ePaper yourself

Delete template?

Save as template?